For more rheumatology education, explore the Content Rheum and the RhAPP ACE app.

Learn how excess adipose tissue contributes to a pro-inflammatory state by elevating cytokines such as Tumor Necrosis Factor alpha, Interleukin-6, and Interleukin-17—key drivers of joint inflammation, enthesitis, and skin manifestations. The video also explains how obesity may reduce the effectiveness of biologic therapies like TNF inhibitors, making weight management a critical component of comprehensive care.

Additionally, this module reviews the link between psoriatic arthritis and Metabolic Syndrome, emphasizing the role of central obesity and metabolic dysfunction in worsening disease burden. A featured 2019 clinical study demonstrates that significant weight loss—achieved through a very low-calorie diet—led to meaningful improvements in disease activity, including reduced joint counts, lower CRP levels, improved psoriasis severity, and enhanced physical function. Notably, patients achieving minimal disease activity nearly doubled, with sustained benefits observed up to 24 months.

This video underscores the importance of integrating weight reduction strategies alongside pharmacologic therapy to optimize outcomes in psoriatic arthritis. Discover how lifestyle interventions can create a synergistic effect with disease-modifying treatments to improve long-term patient outcomes.

For more expert-driven rheumatology education, visit the RhAPP platform, explore the Content Rheum, or download the RhAPP ACE App for on-the-go learning.

#PsoriaticArthritis #Rheumatology #ObesityAndInflammation #APPeducation #BiologicTherapy #TNFinhibitors #MetabolicSyndrome #ContentRheum #RhAPP

For more expert-driven rheumatology education, visit the RhAPP Content Rheum and the RhAPP ACE app.

The discussion highlights practical considerations for advanced practice providers, including weight-based dosing, infusion strategies, and the importance of premedication and hydration to reduce adverse effects. Key safety risks such as thrombosis, renal complications, and infusion reactions are reviewed, along with strategies to minimize these risks. The episode also addresses common challenges with insurance approval and patient access, offering real-world tips to navigate these barriers.

With additional insights on subcutaneous options, brand differences, and monitoring considerations like IgA levels, this episode provides a concise, practical guide to safely and effectively incorporate IVIG into rheumatology care.

#IVIG #Rheumatology #AutoimmuneDisease #APPs #ClinicalEducation #Immunology

The analysis highlights rapid and sustained improvements with guselkumab, with joint symptom relief seen as early as week 2 and broader disease activity improvements by week 8, maintained through 2 years. Across multiple severity cohorts, patients treated with guselkumab were significantly more likely to achieve and maintain low disease activity compared to placebo, with consistent efficacy across both every-4-week and every-8-week dosing regimens. These findings reinforce the importance of early biologic intervention and support guselkumab as a strong first-line treatment option for patients with severe PsA.

Visit the RhAPP Content Rheum and the RhAPP ACE app for more rheumatology education.

Patients with both obesity and psoriatic arthritis often experience poorer outcomes, including higher disease activity scores (DAPSA), increased joint pain, and reduced likelihood of achieving low disease activity or remission. Obesity also contributes to reduced effectiveness of conventional DMARDs and biologic therapies, making disease management more challenging. In addition to systemic inflammation, increased adiposity places mechanical stress on joints, further worsening pain and functional limitations.

This video highlights the complex relationship between metabolic dysfunction and immune response, emphasizing that obesity is not just a comorbidity but a key driver of more severe psoriatic arthritis and diminished therapeutic response. Understanding this connection is essential for improving patient outcomes and optimizing treatment strategies in rheumatology.

For more educational content, visit the RhAPP content rheum or explore the RhAPP ACE app.

This expert discussion dives into key clinical considerations such as induction versus maintenance strategies, patient selection, safety, and real-world implementation of SubQ therapies. The episode also emphasizes the importance of multidisciplinary collaboration between rheumatology and GI providers, especially when managing patients with overlapping conditions like psoriatic arthritis and axial spondyloarthritis. Listeners will gain practical insights on optimizing treatment decisions, enhancing patient education, and leveraging a shared “toolbox” of therapies to better manage complex, multi-system disease.

For more expert-driven education and cross-specialty insights, subscribe to RhAPPcast and visit RhAPP.org, the Content Rheum & the RhAPP ACE app.

For more rheumatology education, podcasts, and expert-led content, explore the Content Rheum and the RhAPP ACE app.

#PsoriaticArthritis #AxialPsA #MRIImaging #Rheumatology #APPeducation #Sacroiliitis #InflammatoryBackPain

The discussion also highlights the role of leptin, a hormone produced by fat cells that regulates appetite and immune signaling. In obesity, elevated leptin levels can disrupt normal metabolic signals and promote immune dysregulation, which may worsen inflammatory and autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, and psoriasis.

For more rheumatology education and APP-focused learning, visit the RhAPP Content Rheum or the RhAPP ACE app.

For more rheumatology education and APP-focused clinical insights, visit the RhAPP website or explore the RhAPP ACE app.

#Rheumatology #PsoriaticArthritis #Spondyloarthritis #Enthesitis #Ultrasound #APPeducation

The episode also provides practical guidance for rheumatology clinicians and advanced practice providers on integrating low ALP awareness into routine clinical assessments, avoiding missed diagnoses, and recognizing that adult hypophosphatasia may be more common than previously thought. Listeners will learn how identifying genetic causes of low ALP can improve patient outcomes, guide appropriate management, and even help uncover undiagnosed cases within families. This discussion offers valuable insights for rheumatology providers involved in bone health, osteoporosis evaluation, and the investigation of unexplained musculoskeletal complaints. For more rheumatology education visit the Content Rheum or the RhAPP ACE app.

#Rheumatology #Hypophosphatasia #LowALP #BoneHealth #Osteoporosis #GeneticDisorders #RheumatologyAPP #MedicalEducation #MusculoskeletalHealth

The conversation highlights early screening for overlapping immune-mediated inflammatory diseases (IMIDs), recognizing subclinical gut inflammation, and selecting cross-indication therapies such as JAK inhibitors and IL-23 inhibitors based on disease severity, comorbidities, and cardiovascular risk. Listeners will gain practical insights into biomarker use (including fecal calprotectin), second-line treatment strategies after TNF failure, and the importance of real-time collaboration between rheumatology and GI providers to optimize patient outcomes.

For more educational content, visit the Content Rheum, RhAPP ACE app, or RhAPP.org.

Listeners will also hear practical insights on patient selection, treatment goals, safety considerations, and how to talk with patients about preventing permanent joint damage before it occurs. This episode is a helpful resource for rheumatology clinicians and advanced practice providers looking to better understand the role of guselkumab in psoriatic arthritis treatment and long-term joint preservation. For more educational content, visit RhAPP.org, Content Rheum or the RhAPP ACE app.

#PsoriaticArthritis #Guselkumab #Rheumatology #IL23 #JointDamage #Biologics #PsA #RheumatologyAPP #RhAPPcast #MedicalEducation

The video also explains how guselkumab fits into the current JPsA treatment landscape alongside TNF inhibitors, abatacept, ustekinumab, secukinumab, and JAK inhibitors, with key considerations including uveitis risk, inflammatory bowel disease implications, paradoxical TNF-induced psoriasis, and safety profile. This overview provides practical guidance for pediatric rheumatology providers tailoring biologic therapy for children with juvenile psoriatic arthritis.

For more rheumatology education, visit the RhAPP Content Rheum or the RhAPP ACE app.

#Hypophosphatasia #HPP #TNSALP #ALPL #Rheumatology #BoneMineralization #GeneticDisorders #AdvancedPracticeProviders #RhAPP #RheumEducation

The conversation examines the immunologic mechanisms linking adiposity to chronic inflammation, including the role of cytokines such as TNF and IL-17, and how obesity amplifies disease across key domains like peripheral arthritis, enthesitis, dactylitis, skin disease, and axial involvement. Drawing from both current evidence and decades of clinical experience, the speakers discuss why weight assessment should be considered an essential component of psoriatic arthritis evaluation and how to approach this topic in a patient-centered, non-stigmatizing way.

For more rheumatology education, check out the Content Rheum on RhAPP.org or explore more education on RhAPP ACE 2.0.

For more information, please visit RhAPP.org, the Content Rheum or the RHAPP ACE 2.0 app.

Joined by Jessica Farrell, PharmD, and Dr. Monica Schwarzman, the discussion explores where IL-23 inhibitors fit relative to methotrexate, TNF inhibitors, and IL-17 inhibitors, with thoughtful analysis of treatment persistence, safety profiles, radiographic progression, and comorbidity considerations, including inflammatory bowel disease. The episode also addresses evolving practice patterns, payer access considerations, and why many clinicians are moving toward earlier use of targeted biologic therapy in appropriate patients.

Additional insights include the role of radiographic progression prevention, interpretation of modified Sharp scores, and future directions in PsA care—such as axial psoriatic arthritis, combination biologic therapy, difficult-to-treat disease, and emerging oral and long-acting agents.

Subscribe to Across the Rheum for ongoing expert-led discussions on evolving therapies in rheumatology.

The discussion reviews common musculoskeletal features such as chronic bone pain, enthesitis, stress fractures, and functional limitations, along with conditions HPP is often mistaken for, including osteoporosis, fibromyalgia, and seronegative rheumatoid arthritis. Special attention is given to persistently low alkaline phosphatase (ALP) levels and why they should prompt further evaluation rather than being dismissed.

This episode provides practical guidance on recognizing red flags, using additional laboratory testing such as fasting phosphorus and vitamin B6, and supporting patients through a long and often frustrating diagnostic journey. Learn more rheumatology education on the RhAPP Content Rheum or through the RhAPP ACE app.

The discussion highlights practical screening strategies for frontline providers, including the Psoriasis Epidemiology Screening Tool (PEST) for identifying PsA risk in patients with psoriasis, as well as referral criteria for spondyloarthritis based on inflammatory back pain features and ASAS recommendations. Key red flags such as early-onset chronic back pain, morning stiffness, extra-articular symptoms, and family history are reviewed.

For gastrointestinal symptoms, the episode explores how tools like CalProQuest and alarm features such as chronic diarrhea, rectal bleeding, anemia, and weight loss can help distinguish IBD from functional GI disorders. This FAQ offers practical guidance to shorten diagnostic delays, support timely referrals, and improve long-term outcomes. Learn more on the RhAPP Content Rheum or in the RhAPP ACE App.

Joined again by Jessica Farrell, PharmD, and Dr. Monica Schwarzman, the conversation examines p19 vs p40 IL-23 inhibition, compares key clinical trial efficacy data in both psoriasis and psoriatic arthritis, and discusses how these data may inform real-world treatment decisions. The episode also explores class switching, limitations of cross-trial comparisons, and the evolving role of head-to-head studies in rheumatology.

This episode is designed for rheumatology clinicians and APPs seeking practical insight into how IL-23 inhibitors are differentiated and positioned in modern PsA management.

Stay tuned for Part 3, where the series concludes with clinical positioning and real-world application of IL-23–directed therapies.

The episode provides a practical overview of HPP pathophysiology, including the role of tissue-nonspecific alkaline phosphatase (TNSALP), the accumulation of key substrates such as inorganic pyrophosphate and pyridoxal-5-phosphate, and how these defects lead to impaired bone and tooth mineralization. We review the wide spectrum of clinical manifestations across children and adults, from rickets, growth failure, and premature tooth loss in pediatrics to osteomalacia, fractures, chondrocalcinosis, and chronic musculoskeletal pain in adults.

For more education on HPP visit the RhAPP Content Rheum or download the RhAPP ACE app.

In Episode 1, the series sets the foundation with an in-depth discussion of IL-23 immunology and its role in the pathophysiology of psoriatic disease. Joined by expert guests Jessica Farrell, PharmD, and Dr. Monica Schwarzman, listeners gain a structured understanding of the IL-23/Th17 pathway, cytokine signaling, and how these mechanisms translate into targeted therapeutic strategies for psoriatic arthritis and related immune-mediated diseases.

Designed for rheumatologists, advanced practice providers, pharmacists, and clinicians involved in inflammatory arthritis care, this episode examines why IL-23 has emerged as a critical therapeutic target, the scientific rationale behind selective inhibition, and how evolving immunologic insights are shaping modern treatment decisions. The discussion also highlights key distinctions between IL-23– and IL-17–driven disease, implications for axial involvement, and the future of precision therapy in psoriatic arthritis.

This episode is cross-hosted on Arthros and the RhAPPcast, the official podcast of Rheumatology Advanced Practice Providers, with sincere thanks to RhAPP for their continued partnership. Educational support for this activity is provided by Johnson & Johnson.

Subscribe to Across the Rheum to continue the series in Episode 2, where the conversation shifts to a detailed review of currently available IL-23 inhibitors, clinical trial data, and practical positioning in today’s rheumatology treatment landscape.

#IMID #ObesityMedicine #ObesityCare #ChronicInflammation #APPEducation #DermatologyPA #Gastroenterology #Rheumatology

#RhAPP #Rheumatology #Pulmonology #ILD #PHILD #APPeducation #RheumatologyConference #MedicalPodcast

#RheumatologyEducation #APEXTrial #BiologicTherapies #AdvancedPracticeProviders #AutoimmuneDisease #JointHealth

#Rheumatology #RA #PMR #Sarilumab #APPeducation #PatientCare #RheumatoidArthritis #PolymyalgiaRheumatica #RheumatologyAPPs #AutoInjector

For more rheumatology education and patient resources, visit RhAPP.org or download the RhAPP ACE App.

#Sarilumab #RheumatoidArthritis #PMR #PolymyalgiaRheumatica #Rheumatology #BiologicTherapy #Kevzara

#PolymyalgiaRheumatica #PMR #Rheumatology #SteroidSparingAgents #Methotrexate #Sarilumab #PMRTreatment #AutoimmuneDisease #RheumatologyEducation

A unique aspect of Leflunomide is its enterohepatic recycling, which allows its active metabolite to persist in the body for an extended period—even years after discontinuation. In cases of toxicity (such as liver enzyme elevations or alopecia) or if a pregnancy is planned, a cholestyramine wash can be used to effectively eliminate the drug from the system. While Leflunomide is generally well tolerated, clinicians should be mindful of its impact as patients age, since declining kidney and liver function may necessitate dose adjustments or discontinuation.

For more expert insights and digital resources, visit the RhAPP website and RhAPP ACE App for the latest in rheumatology education.

#PMR #PolymyalgiaRheumatica #SteroidSparing #Methotrexate #Sarilumab #IL6Inhibitor #Rheumatology #AutoimmuneDisease #Glucocorticoids #SteroidTapering #ChronicInflammation #RhAPP

Methotrexate is a folate antimetabolite that plays a crucial role in inhibiting DNA synthesis, repair, and cellular replication, making it a widely used treatment for autoimmune diseases and certain cancers. Its primary mechanism involves binding to and inhibiting dihydrofolate reductase (DHFR), which prevents the formation of reduced folate, a key component in DNA and RNA synthesis. This inhibition is why folic acid supplementation is recommended for patients taking methotrexate. Additionally, methotrexate blocks thymidylate synthase (TS), further disrupting purine and pyrimidine synthesis, leading to decreased cell proliferation.

Beyond its effects on cellular replication, methotrexate exerts powerful anti-inflammatory properties by interfering with dendritic cell and T-cell communication, reducing pro-inflammatory cytokines, and increasing adenosine levels at sites of inflammation. These actions help suppress immune system overactivity, making methotrexate a cornerstone therapy in conditions like rheumatoid arthritis, psoriasis, and other autoimmune diseases. Furthermore, methotrexate promotes cell apoptosis, contributing to its efficacy in disease management.

For more insights into methotrexate, its uses, and best practices for patient care, visit the RhAPP website or explore additional educational content on the RhAPP ACE App.

Listeners will gain valuable insight into recent clinical trial data, including promising Phase 2 and Phase 3 results in PsA, as well as long-term safety outcomes from psoriasis studies with over five years of data. Eileen shares her practical clinical perspective on where TYK2 inhibitors may fit within the current PsA treatment landscape—especially for patients seeking oral options, those with comorbidities, or those who struggle with adherence to injectable or monitored therapies. The episode also highlights the findings from a recent expert consensus panel published in the Journal of Drugs in Dermatology, supporting the favorable safety profile of deucravacitinib without the need for extensive lab monitoring.

Whether you're a rheumatology provider, fellow, or someone exploring new therapeutic strategies, this episode delivers actionable insights into precision medicine and the future of TYK2-targeted care.

Explore more expert content at RhAPP.org or download the RhAPP ACE app.

Jessica Farrell explains the weight-based dosing strategy (5 mg/kg/day) to minimize the risk of retinal toxicity, discusses its crucial role in lupus management, and highlights its use during pregnancy, particularly in patients with anti-SSA and anti-SSB antibodies to help prevent neonatal heart block. She also shares clinical pearls on managing tolerability issues, including desensitization protocols for patients who experience mild hypersensitivity reactions.

For more expert insights on rheumatology treatments and the latest clinical updates, visit RhAPP.org and explore the RhAPP ACE 2.0 App for digital education.

#Hydroxychloroquine #LupusTreatment #RheumatoidArthritis #Rheumatology #AutoimmuneDisease #LupusCare #RA #RhAPP

Christy breaks down how TYK2’s selective inhibition of the pseudokinase domain—versus the broader catalytic inhibition seen with JAK1, JAK2, and JAK3—can reduce risks associated with immunosuppression, such as major adverse cardiovascular events (MACE), malignancy, and thrombosis. She reviews safety findings from pivotal clinical trials in plaque psoriasis and psoriatic arthritis, where deucravacitinib demonstrated a favorable safety profile and limited systemic immunosuppressive effects.

Watch now to understand why TYK2 selectivity matters—and how it may shape the future of treatment in immune-mediated diseases like psoriasis and PsA.

Visit https://rhapp.org or download the RhAPP app for more expert insights and updates on TYK2 inhibition.

She emphasizes the importance of regular urine tests, protein-creatinine ratio checks, and full blood panels to track disease progression and adjust treatment as needed. Monitoring should be done at every visit, especially after starting new medications, with particular attention to trends in protein levels to guide treatment decisions. Additionally, Monica highlights the critical role of medication adherence, noting that treatment failure is sometimes due to missed doses rather than ineffective therapy. By consistently tracking lab results and confirming patient compliance, healthcare providers can optimize lupus nephritis management.

For more expert insights, visit the RhAPP website or explore additional educational content on the RhAPP ACE App.

This video is a must-watch for rheumatologists, nephrologists, nurse practitioners, and lupus patients looking to stay updated on evidence-based monitoring strategies.

In this discussion, Audrey reviews key findings from a pivotal clinical trial by Landewé et al., which examined the recapture and retreatment rates of Ixekizumab in axial spondyloarthritis (axSpA) after therapy withdrawal. The randomized, placebo-controlled study followed 155 patients with axSpA who achieved remission and were either continued on Ixekizumab or switched to placebo.

Key results from the study revealed that 96% of patients who withdrew to placebo were able to recapture low disease activity upon retreatment, while 71% regained inactive disease status. These findings offer critical insights for rheumatology providers counseling patients who experience therapy interruptions due to illness, infection, surgery, or personal choice.

This discussion provides a valuable clinical perspective on IL-17 inhibitor retreatment strategies and helps answer common patient concerns about treatment withdrawal and re-initiation.

For more expert insights on IL-17 inhibition and axial spondyloarthritis management, visit RhAPP.org or explore additional educational content on the RhAPP ACE App.

These updated recommendations emphasize precision and safety, focusing on minimizing steroid exposure while maximizing disease control through multi-targeted immune therapy.

For more rheumatology insights and clinical updates, visit the Content Rheum at RhAPP.org or download the RhAPP ACE app.

#LupusNephritis #ACRGuidelines #RheumatologyEducation #SteroidTapering #Belimumab #Hydroxychloroquine #Mycophenolate #TripleTherapy #AutoimmuneDisease #RhAPP #ContentRheum

Iris also discusses common side effects, such as upper respiratory infections, CPK elevations, mouth ulcers, and acne, as well as rare cases of rhabdomyolysis—both of which were manageable and non-recurring. She emphasizes that current data does not support a need for regular lab monitoring, though screening for TB and hepatitis remains recommended. This video offers a practical, clear overview of the latest safety data on deucravacitinib and is a must-watch for clinicians, students, and anyone interested in innovative, targeted treatments for autoimmune diseases. For more information, visit RhAPP.org and subscribe for additional expert-led rheumatology education.

This update also explores the long-term extension data from AURORA-2 and aligns these findings with current lupus nephritis treatment guidelines, which now support triple therapy—including voclosporin—for patients with class V or proliferative disease. With its fast-acting and steroid-sparing profile, voclosporin continues to emerge as a valuable therapeutic option for managing active lupus nephritis. For more expert-led rheumatology education, visit RhAPP.org and explore the Content Rheum.

Learn how TYK2 selectively mediates cytokines like IL-12, IL-23, and Type I Interferons, and why allos­teric inhibition at the regulatory domain reduces off-target effects compared to traditional JAK inhibitors. Iris explains the differences between orthosteric vs. allosteric binding, and how deucravacitinib offers a more targeted, safer approach to reducing inflammation in autoimmune diseases.

Learn more about TYK2 inhibition and psoriasis treatment options at RhAPP.org or download the RhAPP ACE app for more educational content.

Stream the RhAPPcast wherever you get your podcasts, and download the new RhAPP ACE 2.0 App to access exclusive learning modules, expert forums, and more. For additional resources, visit RhAPP.org.

This discussion highlights recent findings from the CorEvitas Psoriatic Arthritis and Spondyloarthritis Registry, which assessed six-month persistence and effectiveness rates in adult PsA patients. The study revealed that nearly 80% of patients continued Guselkumab treatment over six months, experiencing significant improvements in disease activity, including joint symptoms, skin manifestations, and patient-reported pain.

Cassie also examines how these findings align with phase three clinical trial data, including DISCOVER-1, DISCOVER-2, and COSMOS trials, where Guselkumab demonstrated high retention rates among patients with active PsA, including those who had previously failed TNF inhibitors. Additionally, she reviews a retrospective study from Spain that found high persistence rates at two years in patients using Guselkumab for PsA or psoriasis in clinical practice.

The discussion underscores Guselkumab’s consistent efficacy in treating psoriatic arthritis both in controlled trials and real-world settings.

For more expert insights on PsA management and biologic therapies, visit RhAPP.org and explore the RhAPP ACE App for the latest updates.

You'll learn how TYK2 plays a critical role in mediating pro-inflammatory cytokines such as IL-12, IL-23, and type I interferons, all of which contribute to the pathogenesis of autoimmune diseases. Iris uses vivid analogies to simplify complex immunologic mechanisms, covering how cytokine signaling triggers downstream inflammation, keratinocyte hyperproliferation, and joint damage in psoriatic conditions.

Discover how TYK2 inhibition can "dial down" the immune response without fully shutting it off—providing targeted, effective treatment with fewer side effects.

Learn more about TYK2 signaling, cytokine pathways, and innovative therapies in rheumatology at RhAPP.org or download the RhAPP ACE app.

IL-17A and IL-17F play central roles in inflammation and autoimmune disease, but their unique functions mean that blocking them can yield different clinical effects. Will explains the pathophysiology of these cytokines, their impact on diseases like psoriatic arthritis and axial spondyloarthritis, and how emerging therapies are targeting both IL-17A and IL-17F for broader disease control.

They also dive into real-world applications, including the latest clinical trials and how IL-17 inhibitors compare in efficacy, safety, and patient selection. Learn why dual inhibition of IL-17A and IL-17F may offer additional benefits over targeting IL-17A alone and what considerations are essential when prescribing these biologics.

For more expert-driven rheumatology content, visit RhAPP.org and explore the RhAPP ACE App for the latest updates, research, and clinical insights.

First, Daric breaks down a post-hoc analysis from the SPIRIT-H2H trial, comparing ixekizumab vs adalimumab in PsA patients with nail disease. The data suggest that nail involvement at baseline may be associated with a more robust clinical response—particularly with IL-17 inhibitors—highlighting the importance of considering specific psoriatic domains like nail psoriasis when tailoring treatment. Amanda then discusses a pooled post-hoc analysis of three phase 3 trials of guselkumab, evaluating the impact of prior TNF inhibitor exposure and baseline disease activity on achieving minimally clinically important improvement (MCII). Findings show that patients with higher baseline disease severity required greater improvement to perceive a benefit, but still responded well to IL-23 inhibition, even after TNF failure.

This episode offers key takeaways for advanced practice providers, especially around optimizing PsA management using precision medicine approaches. From choosing the right therapy for patients with nail disease to understanding how past biologic exposure influences outcomes, Amanda and Derek offer real-world insights grounded in the latest data.

Be sure to catch Parts 1 and 2 of our ACR Wrap-Up for a full view of the PsA updates from ACR Convergence 2024. And don’t forget to follow RhAPP on LinkedIn, Instagram, Facebook, and X for more education, community, and clinical resources in rheumatology.

#PsoriaticArthritis #ACRConvergence2024 #NailPsoriasis #Ixekizumab #Guselkumab #IL23Inhibitors #TNFFailure #MCII #PrecisionMedicine #RheumatologyPodcast #AdvancedPracticeProvider #RhAPP #PsARealWorldData #RheumatologyEducation

In this episode, we examine two important abstracts with major clinical implications:

Does smoking impact biologic drug retention in PsA? Daric dives into a large European cohort study evaluating how smoking and BMI affect the durability of secukinumab, revealing a notable link between smoking and increased treatment discontinuation—echoing similar patterns seen in TNF inhibitors.

Are certain PsA therapies more cardioprotective than others? Amanda breaks down a VA multi-center cohort study analyzing the effect of systemic immunosuppressive therapy on cardiovascular risk in PsA patients. The findings suggest that IL-17 and IL-23 pathway inhibitors may offer superior protection against cardiovascular events compared to traditional treatments, raising questions about how we approach comorbidity management in inflammatory arthritis.

This episode is packed with practical takeaways for advanced practice providers who are managing PsA patients with comorbid conditions like smoking, obesity, and cardiovascular disease. Amanda and Derek also share real-world strategies to enhance patient care, from baseline labs to interdisciplinary referrals.

Stay tuned for Part 3, where we’ll continue reviewing the most relevant PsA abstracts from ACR Convergence 2024.

#PsoriaticArthritis #ACRConvergence2024 #Secukinumab #CardiovascularRisk #IL17Inhibitors #SmokingCessation #RheumatologyPodcast #AdvancedPracticeProviders #RhAPP #BiologicTherapy #PsAComorbidities #PrecisionMedicine #RheumatologyEducation

Together, Amanda and Daric review key data from several abstracts—highlighting oral treatment options, the significance of dosage on efficacy, and the potential advantages of TYK2 inhibition over JAK inhibitors. They also examine results from the FOReMOST trial, evaluating apremilast in patients with early, oligoarticular PsA—a subgroup often underrepresented in clinical studies.

This episode offers practical takeaways for advanced practice providers managing PsA, emphasizing the growing importance of precision medicine and individualized treatment plans. Whether you're navigating treatment for mild disease or considering alternatives for patients with multiple therapy failures, this conversation will help you stay up to date with the evolving PsA landscape.

Don’t forget to subscribe so you don’t miss Part 2 of our ACR Convergence PsA breakdown!

#PsoriaticArthritis #ACRConvergence2024 #TYK2Inhibitor #Apremilast #RheumatologyPodcast #AdvancedPracticeProvider #RhAPP #OralTherapyForPsA #PrecisionMedicine #RheumatologyEducation

Clinical trials like VOYAGE, NAVIGATE, ECLIPSE, and DISCOVER highlight its effectiveness in improving joint and skin symptoms, while real-world data from the CorEvitas PsA and SpA Registry shows 72% of patients remain on Guselkumab after 12 months, compared to just 44% on TNF inhibitors. Kyle shares patient cases that demonstrate how IL-23 inhibition is reshaping PsA treatment, offering comprehensive disease control, improved adherence with its once-every-eight-weeks dosing schedule, and a monotherapy option without methotrexate.

This conversation is essential for rheumatology providers, NPs, and PAs looking to optimize PsA treatment strategies. Learn why IL-23 inhibitors are gaining momentum and how real-world evidence supports Guselkumab’s long-term efficacy and safety.

For expert insights on PsA management and IL-23 inhibitors, visit RhAPP.org or explore the RhAPP ACE App for the latest in rheumatology education.

Jessica Farrell discusses key considerations before initiating voclosporin in patients with lupus nephritis, such as baseline eGFR, blood pressure, and ongoing laboratory assessments. Discover the recommended monitoring schedule for renal function, urine protein, blood pressure, and potassium levels, as well as important safety warnings including the risk of infections, malignancy, neurotoxicity, and QT prolongation.

Find out how voclosporin may have a more favorable impact on lipids and glucose compared to other calcineurin inhibitors, and why proper patient selection and routine monitoring are essential for optimal outcomes in lupus nephritis care.

For more expert resources on voclosporin and lupus nephritis, visit the RhAPP website or download the RhAPP ACE app. Don’t forget to join us at the annual RhAPP conference in September for the latest updates in rheumatology care.

#Voclosporin #LupusNephritis #Rheumatology #PharmacistEducation #CalcineurinInhibitor #RhAPP #LupusTreatment #PatientCare

Methotrexate, while commonly used in PsA treatment, is not FDA-approved for PsA in the U.S., yet it is often required by insurance companies before biologic therapy. Clinical guidelines, including EULAR, ACR, and GRAPPA, recommend MTX for peripheral arthritis, but this is largely based on observational data rather than robust randomized controlled trials (RCTs).

The meta-analysis, published in Rheumatic & Musculoskeletal Diseases (RMD), examined randomized double-blind controlled trials and compared biologic monotherapy versus combination therapy with MTX using ACR 20, 50, and 70 responses. The study found no statistically significant difference between biologics alone or in combination with MTX, suggesting that MTX does not enhance biologic efficacy in PsA.

These findings reinforce the argument that biologic monotherapy may be a better first-line option for PsA and should be considered when advocating for insurance approvals.

For more expert discussions, visit RhAPP.org or explore the latest educational content on the RhAPP ACE App.

Jessica discusses the long-term safety and efficacy findings from AURORA 2, highlighting the sustained renal benefits, lower risk of renal flares, and the drug’s manageable safety profile over three years of treatment. She also addresses key trial limitations, the significance of steroid reduction, and the need for further long-term data.

For more expert insights on rheumatology treatments and lupus nephritis management, visit RhAPP.org and explore the RhAPP ACE App.

#LupusNephritis #Voclosporin #Rheumatology #ClinicalTrials #AuroraStudy #Nephrology #AutoimmuneDisease #RhAPP

Voclosporin is a next-generation calcineurin inhibitor that works by inhibiting T-cell activation, reducing the inflammatory response that leads to kidney damage in lupus nephritis. Unlike traditional CNIs like cyclosporine and tacrolimus, Voclosporin features a more consistent pharmacokinetic profile, minimizing variability in drug levels and improving patient outcomes. It is now an integral component of triple therapy in the latest American College of Rheumatology (ACR) 2024 Lupus Nephritis Guidelines, recommended alongside mycophenolate mofetil (MMF) and glucocorticoids for Class III and IV lupus nephritis.

Understanding proper dosing and administration is critical for maximizing Voclosporin’s therapeutic effects. The standard dose is 23.7 mg twice daily, taken on an empty stomach—one hour before or two hours after meals—to ensure optimal absorption. For patients with renal impairment, dose adjustments are required based on estimated glomerular filtration rate (eGFR) to prevent nephrotoxicity. Routine kidney function monitoring is essential, with frequent eGFR assessments to detect early signs of kidney dysfunction.

One of the most important considerations with Voclosporin is its impact on blood pressure regulation, as it can contribute to hypertension. Close monitoring for hypertensive emergencies is crucial, particularly in patients with preexisting cardiovascular conditions. Clinicians must also be aware of drug interactions, especially with CYP3A4 inhibitors and P-glycoprotein substrates, which can alter Voclosporin metabolism and lead to potential toxicity.

Patients and providers should also be informed about common side effects, including neurotoxicity, hyperkalemia, QT prolongation, increased infection risk, and heightened sun sensitivity, all of which require proactive management. Given its potential effects on fetal development, Voclosporin is contraindicated in pregnancy, necessitating careful contraceptive counseling for women of childbearing potential. Breastfeeding is also not recommended while on therapy due to potential drug transfer to breast milk.

As an emerging cornerstone in lupus nephritis treatment, Voclosporin represents a significant advancement in immunosuppressive therapy, offering increased efficacy with a more predictable pharmacokinetic profile. By integrating Voclosporin into treatment plans while carefully monitoring for adverse effects, clinicians can improve long-term kidney function and overall disease management in lupus nephritis patients.

For more expert insights and the latest advancements in rheumatology, visit RhAPP.org or download the RhAPP ACE App for clinical resources and educational updates. Stay informed on cutting-edge treatments shaping the future of autoimmune disease management.

As a phase 3 clinical trial, DISCOVER-2 evaluated Guselkumab in biologic-naïve patients with active PsA over two years, comparing 100 mg every 4 weeks and 100 mg every 8 weeks to placebo. At week 24, significantly more patients on Guselkumab achieved ACR20 response rates, demonstrating its superior ability to control inflammation and joint symptoms.

A post-hoc analysis of DISCOVER-2 stratified patient responses across GRAPPA domains, including peripheral arthritis, axial disease, enthesitis, dactylitis, and psoriasis, confirming early and sustained improvement through 100 weeks of therapy. While nail disease was not directly assessed in DISCOVER-2, pooled data from VOYAGE-1 and VOYAGE-2 trials revealed that Guselkumab significantly improved nail psoriasis, with patients achieving clearance or minimal disease activity by week 16.

With consistent results in long-term disease control, Guselkumab stands out as a comprehensive treatment choice for PsA patients, addressing multiple disease manifestations beyond joint inflammation. Its strong safety profile and efficacy in biologic-naïve patients further support its role as a go-to IL-23 inhibitor in PsA management.

For more expert insights on Guselkumab and its role in PsA treatment, visit RhAPP.org or explore the RhAPP ACE App for the latest educational content in rheumatology.

The SPIRIT H2 trial, a head-to-head comparison of Ixekizumab (IL-17A inhibitor) versus Adalimumab (TNF inhibitor) in biologic-naïve PsA patients, provides valuable insights into the best treatment approach. A post-hoc analysis of the trial included 354 patients with both DIP arthritis and nail involvement, assessing over 1,000 affected finger units. The study revealed that patients treated with Ixekizumab experienced greater resolution of DIP joint tenderness and swelling along with improvements in adjacent nail psoriasis compared to those receiving Adalimumab. These benefits were observed as early as 12 weeks and were sustained through 52 weeks, highlighting the potential superiority of IL-17A inhibition over TNF inhibition for PsA patients with nail disease.

This data underscores the importance of targeted therapy in psoriatic arthritis, particularly in cases where the nail-DIP complex is involved. IL-17 inhibitors like Ixekizumab offer a promising option for patients struggling with both joint inflammation and nail disease.

For more expert insights and clinical resources, visit RhAPP.org or explore the RhAPP ACE App for the latest in rheumatology education.

She discusses common CNIs used in clinical practice, such as tacrolimus, cyclosporine, and the newer agent voclosporin. Voclosporin, in particular, is highlighted for its role in treating LN, including recommended dosing guidelines and considerations for renal or hepatic impairment.

Lisa also breaks down how CNIs fit into the updated 2024 ACR treatment algorithm for lupus nephritis. Triple therapy, which now includes a CNI, is recommended for Class III and IV LN. Class V LN patients should be treated with a glucocorticoid, mycophenolate, and a CNI.

Whether you're a clinician looking to stay current with treatment strategies or an APP diving deeper into rheumatology therapies, this video offers a concise overview of how CNIs are shaping modern LN management. Visit RhAPP.org or download the RhAPP ACE App for more insightful and educational information.

The ECLIPSE trial, published in The Lancet, compared Guselkumab (IL-23 inhibitor) vs. Secukinumab (IL-17 inhibitor) over 48 weeks. Guselkumab showed superior long-term efficacy, with 84% of patients achieving PASI 90 (90% skin clearance) compared to 70% with Secukinumab, both with similar safety profiles.

The EXCEED trial compared Ixekizumab (IL-17) and Guselkumab (IL-23) over 24 weeks. Ixekizumab provided a faster onset of symptom relief, particularly in nail psoriasis, while Guselkumab delivered sustained disease control. In PsA patients, both drugs showed similar joint symptom improvement, reinforcing their viability in treatment.

For rapid symptom relief, IL-17 inhibitors (Ixekizumab, Secukinumab) may be preferable. For long-term stability, IL-23 inhibitors (Guselkumab) stand out. The choice depends on patient needs, disease progression, and treatment goals.

For the latest updates in psoriasis and PsA management, visit the RhAPP website or the RhAPP ACE App.

The study focused on patients with significant psoriasis severity, defined by Static Physician Global Assessment (sPGA) scores of 3 or higher, Psoriasis Area and Severity Index (PASI) scores above 12, and at least 10% body surface area (BSA) involvement. Participants were randomized to receive either Ixekizumab or Guselkumab at their FDA-approved dosing regimens, with a primary endpoint of 100% PASI improvement (PASI 100) at Week 12.

Results revealed a clear difference in speed of response. By Week 12, 41% of patients on Ixekizumab achieved PASI 100, compared to 25% on Guselkumab, a statistically significant difference. Even more compelling, PASI 50 was reached as early as Week 1 in the Ixekizumab group, and PASI 75 was achieved by Week 2, reinforcing its potential as a rapid-acting psoriasis treatment. These findings are critical for patients who are eager to see visible skin improvements quickly, particularly those who experience severe itching, scaling, and emotional distress due to their condition.

Dr. Farrell emphasizes that head-to-head trials are rare in dermatology, making this study highly valuable when considering treatment sequencing in plaque psoriasis. Choosing between IL-17 and IL-23 inhibitors depends on several factors, including mechanism of action, patient history, treatment goals, and potential adverse effects. The study also confirmed that both medications maintained a favorable safety profile, with no new safety concerns emerging during the trial.

For patients with moderate-to-severe plaque psoriasis, access to fast-acting, effective therapies is crucial. With studies like this, healthcare providers can make more informed decisions when prescribing biologic therapies for psoriasis, ensuring that patients receive the most effective treatment tailored to their needs.

For more expert insights into psoriasis management, biologic therapies, and rheumatology advancements, visit RhAPP.org or explore the RhAPP ACE App.

Voclosporin plays a critical role in immune modulation by inhibiting calcineurin, a key enzyme responsible for activating T-cells. By blocking calcineurin activity, Voclosporin prevents the dephosphorylation of NFAT (Nuclear Factor of Activated T-cells), which is necessary for IL-2 transcription. This disruption reduces IL-2 production, lymphocyte proliferation, and surface antigen expression, ultimately dampening the autoimmune response that drives inflammation in lupus nephritis.

As a highly selective and potent calcineurin inhibitor, Voclosporin has been shown to improve kidney outcomes in patients with lupus nephritis, achieving more rapid and sustained reductions in proteinuria compared to traditional calcineurin inhibitors like cyclosporine and tacrolimus. Its optimized pharmacokinetics and predictable dosing make it a valuable addition to the treatment landscape for lupus and other immune-mediated diseases.

This session is essential for healthcare professionals, pharmacists, and patients seeking to understand the evolving role of calcineurin inhibitors in autoimmune therapy. Learn more about the latest advancements in rheumatology and nephrology, and explore how Voclosporin is shaping the future of lupus nephritis management.

For more expert insights and clinical updates, visit RhAPP.org or download the RhAPP ACE App for comprehensive educational resources on emerging treatments in autoimmune disease care.

She discusses the importance of screening all lupus patients every 6 to 12 months, as 30-50% of SLE patients eventually develop lupus nephritis. The updated guidelines recommend renal biopsy for patients with significant proteinuria or unexplained impaired renal function. For Class 3 and Class 4 lupus nephritis, a triple immunosuppressive regimen is conditionally recommended, which may include glucocorticoids, mycophenolate, belimumab, calcineurin inhibitors, or cyclophosphamide. For Class 5 lupus nephritis with proteinuria greater than 1 g/g, triple therapy involving glucocorticoids, mycophenolate, and a calcineurin inhibitor is recommended. The guidelines also emphasize low-dose steroid tapering to minimize toxicity, starting with 0.5 mg/kg/day of prednisone and tapering to ≤5 mg/day by six months.

Additionally, new strong recommendations for monitoring include assessing proteinuria every three months in patients without complete renal response and every three to six months in those with sustained complete renal response.

Stay updated on the latest evidence-based approaches to managing lupus nephritis with these 2024 ACR guidelines. For more educational content please visit RhAPP.org or download the RhAPP ACE 2.0 app.

This discussion highlights a comprehensive integrated analysis of 11 Phase 2 and Phase 3 clinical studies, which pooled over 10,000 patient-years of follow-up data. The results reinforce Guselkumab’s favorable safety profile, demonstrating low rates of severe adverse events, infections, and malignancies, which remained consistent across diverse patient subgroups. Furthermore, adverse event rates during treatment were comparable to those observed during placebo-controlled periods, solidifying Guselkumab as a low-risk, well-tolerated option for long-term management of psoriatic disease.

Visit the RhAPP website or explore additional educational content on the RhAPP ACE App.

This special RhAPPcast episode explores a real-world scenario of a patient who unexpectedly became pregnant while on leflunomide, highlighting the complexities of medication management in autoimmune diseases. Monica shares her initial reaction, the steps taken to initiate the cholestyramine washout protocol, and the multidisciplinary approach needed to ensure both maternal and fetal safety.

Danielle provides critical insights into the pharmacology of leflunomide, including its long half-life, the importance of drug clearance before conception, and patient counseling strategies. They also discuss broader considerations for disease management in women of childbearing age, the role of conventional DMARDs in rheumatology, and lessons learned from this case.

Recorded live at the RhAPP National Conference, this engaging discussion offers valuable takeaways for rheumatology providers navigating pregnancy risks with immunosuppressive therapies.

For more expert insights, visit RhAPP.org and explore the RhAPP ACE App for the latest in rheumatology education.

The updated guidelines focus on achieving a daily glucocorticoid dose of 5 mg or less within six months of initiating therapy. This approach aims to reduce steroid-related adverse effects such as osteoporosis, cardiovascular risks, and metabolic disturbances while maintaining disease control. To achieve this, clinicians must closely monitor disease activity and tailor tapering strategies to each patient’s individual needs.

Frequent patient assessments and laboratory monitoring play a crucial role in ensuring stability throughout the tapering process. Identifying early signs of disease worsening is essential to making timely adjustments and preventing potential flares. By adopting a personalized approach, healthcare providers can optimize outcomes and improve the long-term management of lupus nephritis.

For more expert insights on lupus nephritis treatment strategies, visit the RhAPP website or explore additional educational content on the RhAPP ACE App.

Accurate assessment of PsA requires disease-specific tools beyond traditional rheumatoid arthritis (RA) measures. The Disease Activity in Psoriatic Arthritis (DAPSA) score evaluates joint inflammation using tender and swollen joint counts, CRP levels, and patient-reported assessments. The clinical DAPSA (cDAPSA), an alternative version, removes CRP from the calculation, offering another method to track disease progression.

For a comprehensive view of PsA’s impact, the Minimal Disease Activity (MDA) index goes beyond joint symptoms, assessing enthesitis, skin involvement, pain, function, and patient-reported outcomes. Achieving MDA is a key goal in treat-to-target strategies, guiding adjustments in therapy to improve long-term patient health.

Clinical trials and real-world evidence highlight guselkumab’s efficacy in PsA treatment. The DISCOVER-2 trial found that 25% of biologic-naïve PsA patients on guselkumab achieved MDA by week 24, increasing to 40% over two years. Additionally, real-world registry data from CorEvitas showed that 80% of patients remained on guselkumab at six months, with one in four achieving low disease activity—reinforcing the effectiveness seen in clinical trials.

Understanding and utilizing these PsA-specific disease activity measures helps rheumatology providers make informed treatment decisions and ensure sustained improvements in patient care.

For more expert insights into rheumatology advancements, visit RhAPP.org or explore the RhAPP ACE App.

From the first injection, many patients begin to see significant improvement in their symptoms, including reduced inflammation, joint pain, stiffness, enthesitis, and dactylitis. By the three-month follow-up, clinical data aligns with real-world experiences, showcasing meaningful symptom relief. Claudia recounts patient stories of life-changing transformations—individuals who once hid their skin under long sleeves and struggled with daily activities due to joint pain now confidently enjoy time with their families at the beach, free from discomfort and embarrassment.

Ixekizumab’s rapid onset of action not only improves physical symptoms but also restores quality of life, allowing patients to regain mobility and confidence in ways they never thought possible. For more expert insights on psoriasis and psoriatic arthritis treatments, visit the RhAPP website, explore the Content Rheum hub, and access the latest educational materials on the RhAPP ACE App.

This expert-led discussion explores the latest best practices for lupus nephritis screening, emphasizing why the spot protein-to-creatinine ratio has become the preferred diagnostic tool over the traditional 24-hour urine collection. The shift aims to provide a more efficient and practical approach to identifying early kidney involvement in SLE patients. Monica highlights the importance of performing full urinalysis at every patient visit, a practice that allows for earlier intervention and better disease management.

The discussion also covers when healthcare providers should consider a kidney biopsy to confirm a lupus nephritis diagnosis and determine disease severity. Understanding lupus nephritis classifications and chronicity is crucial for tailoring treatment strategies and preventing long-term kidney damage. Monica shares her real-world insights on proactive patient care, offering guidance on how frequent monitoring can lead to more effective disease control.

For rheumatology professionals, nephrologists, and caregivers, this video provides a comprehensive overview of the evolving landscape of lupus nephritis diagnosis. By staying informed on the latest screening recommendations, healthcare providers can enhance their approach to patient care and contribute to improved outcomes in lupus management.

For more expert discussions on the latest advancements in rheumatology, visit RhAPP.org or explore the RhAPP ACE App.

With the first ACR guideline update since 2012, these new recommendations reflect advancements in therapeutics and a shift toward more targeted treatment approaches. The episode explores key changes, including updated recommendations for lower-dose glucocorticoids, the introduction of triple therapy strategies, and the importance of early intervention in preventing irreversible kidney damage. The discussion also highlights screening protocols, emphasizing the need for regular urine protein monitoring in lupus patients every six to twelve months to detect early signs of kidney involvement.

One of the most significant shifts in the guidelines is the preference for triple therapy over dual therapy for patients with active lupus nephritis. This new approach integrates glucocorticoids with mycophenolate mofetil (MMF) or cyclophosphamide, combined with an additional immunosuppressive agent such as belimumab or a calcineurin inhibitor. The rationale behind this shift is to reduce long-term steroid exposure while improving renal outcomes. The conversation dives into the evidence supporting these recommendations and how providers can implement them effectively in clinical practice.

Beyond treatment selection, the discussion touches on the importance of shared decision-making and addressing healthcare disparities in lupus care. Patients from diverse socioeconomic backgrounds often face barriers to timely treatment, which can significantly impact their prognosis. By fostering strong patient-provider relationships and ensuring open communication, rheumatology teams can better support patients in managing their disease and adhering to treatment plans.

With advancements in lupus nephritis management, providers now have more tools than ever to improve patient outcomes. The insights shared in this episode aim to equip healthcare professionals with the knowledge and strategies needed to implement the latest guidelines in their practice.

Stay informed on evolving lupus nephritis research, treatment guidelines, and clinical insights by visiting RhAPP.org or accessing the latest educational content on the RhAPP ACE App.

Lupus nephritis results from autoantibody-driven kidney inflammation, leading to proteinuria, hypertension, and progressive kidney damage. Without proper management, up to 30% of patients face a 10-year mortality rate, while 10-20% may progress to ESRD. The latest American College of Rheumatology (ACR) guidelines emphasize routine urine protein screening every six to twelve months for lupus patients, with more frequent monitoring in those with known kidney disease. Patients who fail to achieve complete renal response should have kidney function and protein levels checked at least every three months, with biopsy considered for persistent proteinuria or unexplained kidney function decline.

By following updated screening recommendations and initiating treatment early, clinicians can help preserve kidney function and improve long-term outcomes.

Stay informed on the latest lupus nephritis research, treatment strategies, and expert discussions by visiting RhAPP.org or accessing educational content on the RhAPP ACE App.

RCTs, like the Phase 3 COSMOS trial, are designed to eliminate bias by randomly assigning patients to treatment or placebo groups. In COSMOS, Guselkumab (Tremfya) showed significant improvements in joint and skin symptoms for PsA patients who had failed TNF inhibitors, establishing its efficacy in a controlled setting.

RWE, however, reflects real-world treatment patterns and patient outcomes. Unlike RCTs, it includes diverse populations with varied medical histories and prior treatments. A 12-month claims analysis from the IBM MarketScan database found that 72% of PsA patients on Guselkumab maintained treatment persistence, compared to 44% for subcutaneous TNF inhibitors. Additionally, data from the CorEvitas Registry showed that nearly 80% of patients continued Guselkumab for at least six months, with significant symptom improvements.

By considering both RCTs and RWE, clinicians gain a more comprehensive understanding of treatment effectiveness, helping them tailor therapy decisions to each patient’s unique needs.

For more insights into Guselkumab and psoriatic arthritis management, visit RhAPP.org or access educational resources on the RhAPP ACE App.

Previous guidelines relied heavily on high-dose steroids with mycophenolate mofetil (MMF) or cyclophosphamide for induction, followed by MMF maintenance. Now, with the approval of belimumab and voclosporin, treatment strategies emphasize a more targeted and sustained approach. These new options help preserve kidney function while limiting steroid exposure.

The revised recommendations call for a lower-dose glucocorticoid regimen, starting at 0.5 mg/kg per day (max 40 mg) with tapering to 5 mg daily within six months. For Class III and IV lupus nephritis, triple therapy—including glucocorticoids, MMF, and belimumab or a calcineurin inhibitor—is now preferred. In Class V cases with significant proteinuria, MMF and a calcineurin inhibitor remain key components.

Frequent monitoring, particularly urine protein assessments, is crucial for tracking disease progression and preventing irreversible kidney damage. With these updates, clinicians have clearer guidance on optimizing lupus nephritis care while minimizing long-term complications.

Stay informed on the latest lupus nephritis treatment strategies by visiting RhAPP.org and exploring the RhAPP ACE App.

Polymyalgia Rheumatica is traditionally managed with glucocorticoids, but long-term steroid use presents significant risks, especially in patients with diabetes, osteoporosis, or cardiovascular disease. The ACR and EULAR guidelines suggest using Methotrexate as a steroid-sparing agent in patients at high risk of relapse or those requiring prolonged treatment. However, due to limited clinical trial data and conflicting results regarding Methotrexate’s impact on disease progression, Leflunomide is emerging as a potential alternative for steroid reduction and long-term disease control.

This study followed 186 PMR patients from 2007 to 2023, examining treatment outcomes in those prescribed Methotrexate (10-15 mg weekly) or Leflunomide (20 mg daily). While flare rates remained comparable between both treatment groups, the study found that Leflunomide demonstrated a significantly higher remission rate and faster steroid discontinuation compared to Methotrexate. Patients treated with Leflunomide achieved steroid withdrawal within 4.7 months, while those on Methotrexate required an average of 31.8 months. Additionally, Leflunomide patients exhibited a higher probability of sustained remission up to 40 months post-treatment.

The findings of this study suggest that Leflunomide may be a superior steroid-sparing option in PMR, particularly for patients who struggle with Methotrexate tolerability or require faster tapering of glucocorticoids. Although the study had limitations, including its observational design and the relatively low Methotrexate dosing range of 10-15 mg weekly, it provides important clinical insights for rheumatology providers seeking alternative treatment strategies.

With the growing need for effective, steroid-sparing therapies in PMR management, Leflunomide presents a viable option that warrants further research and consideration in clinical practice.

Visit the RhAPP website or explore additional educational content on the RhAPP ACE App.

With IL-23 inhibitors offering durable improvements in spinal pain, BASDAI scores, and ASAS responses, this episode focuses on how Guselkumab is addressing axial symptoms and inflammation in PsA patients, especially those with psoriasis and sacroiliitis. The discussion also differentiates Axial PsA from Axial Spondyloarthritis (AxSpA)—two conditions with overlapping but distinct disease mechanisms.

As a leader in rheumatology education, Amanda Mixon, PA-C, brings her expertise in clinical practice, education, and advocacy to the conversation, while Audrey Gibson, PA-C, shares real-world clinical insights on IL-23 inhibitors and their role in managing PsA.

With the STAR trial set to further evaluate Guselkumab’s effectiveness in AxPsA, this discussion is essential for rheumatology providers looking to refine their treatment strategies and stay ahead of the latest advancements in PsA management.

For more expert insights on PsA and IL-23 targeted therapy, visit RhAPP.org or explore the RhAPP ACE App for the latest educational resources.

The study highlights key differences in treatment response with and without methotrexate. Ixekizumab maintains consistent efficacy regardless of MTX use, making it a potential monotherapy option for PsA patients. In contrast, Adalimumab demonstrates improved efficacy when combined with methotrexate, suggesting that it may be more effective in patients who can tolerate MTX co-therapy.

Results from the study show that Ixekizumab (36-39%) outperforms Adalimumab (28-26%) in patients who do not use methotrexate, reinforcing its role as an effective stand-alone treatment for PsA. These findings support MTX-free biologic options, particularly for patients who are unable or unwilling to use methotrexate due to intolerance or contraindications.

This data provides valuable guidance for rheumatology providers making personalized treatment decisions for PsA patients. Understanding how methotrexate influences biologic efficacy can help optimize therapeutic strategies and improve patient outcomes.

For more expert-led discussions on PsA treatment approaches, visit RhAPP.org or access the latest clinical insights on the RhAPP ACE App.

The mVHS score evaluates joint erosion, joint space narrowing, and periarticular changes, providing a comprehensive view of disease impact. Meanwhile, the MTSS score focuses specifically on bone erosions and joint space narrowing, offering a more targeted measure of progression. By understanding these scoring methods, providers can monitor long-term joint health and adjust therapies accordingly.

The Apex Study, a Phase 3B clinical trial, is further investigating the efficacy of Guselkumab (Tremfya®) in PsA, using mVHS to measure radiographic progression. This builds on findings from the Discover-2 trial, which showed minimal joint damage progression with Guselkumab treatment. As evidence grows for IL-23 inhibition in protecting joint integrity, radiographic monitoring remains essential in optimizing PsA management.

For more expert insights on psoriatic arthritis, radiographic scoring, and the latest advancements in rheumatology, visit RhAPP.org or explore additional educational resources on the RhAPP ACE App.

This discussion highlights how Ixekizumab performs across the diverse manifestations of PsA, including peripheral arthritis, axial disease, enthesitis, dactylitis, and both skin and nail psoriasis. Clinical data demonstrate its impact on ACR 20/50/70 scores, showing improvements in joint symptoms and axial disease response. Additionally, Ixekizumab has been proven effective in resolving enthesitis and dactylitis, reducing inflammation in tendons and digits. Patients with psoriasis also see significant improvements, with high rates of POSI 75/90/100 clearance and reductions in nail psoriasis severity, as measured by NAPSI scores.

Understanding Ixekizumab’s efficacy across GRAPPA domains is critical for healthcare providers selecting targeted therapies that address PsA’s multifaceted symptoms. This video explores how IL-17 inhibitors fit within GRAPPA treatment guidelines and how Ixekizumab can optimize patient care by delivering comprehensive disease control.

For more expert insights on biologics, psoriatic disease, and rheumatology advancements, visit RhAPP.org or explore educational content on the RhAPP ACE App.

The Discover-2 trial provides critical insights into the safety of Guselkumab compared to placebo in biologic-naïve PsA patients, highlighting infection rates and adverse events. Long-term safety data spanning over 11,000 patient-years across multiple phase 2 and phase 3 trials reinforce the consistency of Guselkumab’s safety profile across diverse patient populations.

This discussion breaks down key findings on the incidence of serious infections, adverse events, and overall treatment tolerability, addressing critical questions about Guselkumab’s suitability as a long-term therapeutic option for psoriatic disease.

For more expert insights on biologics, psoriatic disease management, and the latest in rheumatology research, visit RhAPP.org or explore the RhAPP ACE App.

This session delves into critical distinctions between these conditions, including differences in joint involvement, disease progression, and imaging patterns. Genetic markers such as HLA associations and cytokine pathways—including IL-17A, TNF, and IL-10—are explored to better understand their roles in axial disease. Additionally, insights from post hoc analysis of the DISCOVER-1 and DISCOVER-2 trials highlight the efficacy of Guselkumab (Tremfya) in Axial PsA, demonstrating significant improvements in BASDAI scores, spinal pain reduction, and ASDAS response rates.

Understanding the nuances between Axial PsA and AS is crucial for optimizing patient care, selecting appropriate therapies, and improving long-term disease outcomes.

For expert insights on psoriatic arthritis, axial disease, and the latest treatment advances, visit the RhAPP website or explore additional educational content on the RhAPP ACE App.

The study followed PsA patients receiving Guselkumab 100 mg at weeks 0, 4, and then every 8 weeks, assessing disease activity at baseline and again at six months. Key measures included the Clinical Disease Activity in Psoriatic Arthritis (cDAPSA) score, physician global assessment (PGA), patient-reported pain, and psoriasis severity (BSA). Notably, 80% of patients persisted with treatment through six months, showing statistically significant improvements across multiple disease domains. With an average disease duration of 14 years, most participants had prior biologic exposure, making these findings particularly relevant to real-world clinical practice.

Jessica highlights the value of registry data in validating clinical trial results, providing confidence that Guselkumab’s benefits translate beyond controlled study environments into everyday patient care. Real-world evidence helps clinicians set patient expectations and refine treatment strategies for optimal outcomes.

For more expert insights on RA remission, Visit the RhAPP website or explore additional educational content on the RhAPP ACE App.

IL-17 inhibitors have revolutionized the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis, offering targeted therapy for chronic inflammatory conditions. However, emerging data suggest that IL-17 inhibition may influence gut inflammation, raising important considerations for clinicians managing patients with concurrent or potential IBD. This discussion reviews the latest clinical trial data, meta-analyses, and real-world evidence to provide clarity on the relationship between IL-17 blockade and IBD development.

Key takeaways include identifying at-risk patients, implementing proactive monitoring strategies, and optimizing treatment selection for those with overlapping rheumatic and gastrointestinal conditions. Learn best practices for prescribing, monitoring, and patient education to maximize therapeutic outcomes while mitigating risks.

For the latest expert discussions, medication reviews, and clinical insights into rheumatic disease management, visit RhAPP.org or download the RhAPP ACE App.

CD64, a high-affinity receptor expressed on myeloid lineage immune cells, plays a pivotal role in inflammatory signaling. IL-23, a key driver of inflammation in psoriatic arthritis, psoriasis, and inflammatory bowel disease, promotes pathogenic TH17 cell differentiation, contributing to chronic inflammation. Guselkumab (Tremfya) uniquely leverages a dual-binding mechanism, targeting both IL-23 and CD64-positive cells to enhance specificity and therapeutic efficacy.

Insights from the DISCOVER-1 and DISCOVER-2 clinical trials highlight the benefits of IL-23 inhibition in psoriatic disease, demonstrating improved patient outcomes, reduced systemic inflammation, and minimized off-target effects.

For more expert discussions on the latest advancements in rheumatology, visit RhAPP.org or explore the RhAPP ACE App.

This open-label, three-part Phase 1 study evaluated pharmacokinetics, safety, and efficacy in patients aged 2-18 across North America, Europe, and Asia. Results demonstrated promising clinical responses, with an ACR 30 response rate of 92% at Week 12, ACR 50 response of 90%, and ACR 70 response of 69%. Safety data indicated mild-to-moderate adverse events, including upper respiratory tract infections, COVID-19 infections, gastroenteritis, neutropenia, and CPK elevations.

With FDA approval and orphan drug designation granted in June 2024, Upadacitinib represents a potential new treatment option for pediatric JIA, offering targeted JAK1 inhibition to improve disease outcomes.

For more expert insights into pediatric rheumatology, JIA treatments, and clinical trial data, visit RhAPP.org or explore the RhAPP ACE App.

This discussion covers the common barriers to early treatment, including limited specialist access, patient hesitancy, and insurance hurdles, as well as the long-term risks of delayed therapy. Identifying high-risk patients through clinical assessments, disease activity scores, and patient-reported symptoms is essential for early intervention. Additionally, innovative practice efficiency solutions, such as virtual visits, team-based workflows, and improved scheduling strategies, can help streamline care and prevent unnecessary delays.

One critical takeaway is the danger of complacency in disease management. Even when a patient shows some improvement, it may not be enough to prevent long-term damage. Advanced practice providers (APPs) play a pivotal role in advocating for treatment escalation and ensuring that patients receive the most effective therapies as early as possible.

For more expert insights into rheumatology care, visit RhAPP.org or explore the RhAPP ACE App.

This analysis provides valuable insights into treat-to-target strategies in RA, particularly for patients who do not achieve optimal disease control with their initial therapy. The study examines remission and low disease activity (LDA) rates over 228 weeks post-switch, highlighting key outcomes for both non-responders and incomplete responders. Additionally, safety considerations—including herpes zoster risk, lymphopenia, and CPK elevations—are addressed to guide informed treatment transitions.

With ongoing debates over JAK inhibitors vs. TNF inhibitors in RA management, this discussion helps clinicians navigate treatment decisions, optimize patient outcomes, and engage in effective shared decision-making.

For more expert-led discussions on RA treatment strategies, visit RhAPP.org or download the RhAPP ACE App to access Medication Reviews, Journal Clubs, and the latest research in rheumatology.

The Boolean 2.0 criteria evaluate four key factors: tender joint count, swollen joint count, patient global assessment, and CRP levels. Meanwhile, the Index-based definitions rely on the Simplified Disease Activity Index (SDAI) at ≤ 3.3 and the Clinical Disease Activity Index (CDAI) at ≤ 2.8 to determine remission status.

Recent updates to the Boolean criteria in 2022 aimed to improve agreement with the index-based definitions while maintaining accuracy in predicting functional and radiographic outcomes. A study of 248 patients found that remission rates were slightly higher under the new Boolean 2.0 criteria compared to the original 1.0 version. However, overall remission rates remain low, underscoring the continued need for advanced therapies and optimized treatment strategies.

For more expert insights on RA remission, visit the RhAPP website or explore additional educational content on the RhAPP ACE App.

Guselkumab is FDA-approved for psoriasis and PsA and can be used alone or in combination with methotrexate or leflunomide. The standard dosing schedule consists of a 100 mg subcutaneous injection at Week 0 and Week 4, followed by maintenance dosing every 8 weeks.

Before initiating treatment, thorough pre-screening is essential, including TB screening, hepatitis B and C testing, and baseline CBC, BMP, and liver function tests. Regular monitoring ensures patient safety and optimal response to therapy.

Common side effects associated with Guselkumab include upper respiratory infections, injection site reactions, arthralgia, headache, and diarrhea. However, the treatment is well-tolerated and does not require dose adjustments for patients with hepatic or renal impairment.

Guselkumab continues to be a preferred biologic across rheumatology and dermatology, offering targeted IL-23 inhibition for effective management of inflammatory conditions.

For more expert insights into psoriasis and PsA treatments, visit the RhAPP website or explore additional educational content on the RhAPP ACE App.

Achieving remission in RA requires a multifaceted approach, incorporating clinical assessment tools such as tender and swollen joint counts, patient-reported outcomes, and inflammatory markers like CRP. The evolution of RA therapies—from early disease-modifying agents like gold injections to today’s biologics and JAK inhibitors—has dramatically reshaped patient outcomes.

This episode delves into the latest advancements in RA treatment, highlighting the importance of early aggressive intervention, treat-to-target strategies, and personalized medicine. It also examines the barriers to remission, including treatment adherence, insurance limitations, and patient misconceptions.

For APPs, optimizing RA management involves frequent follow-ups, shared decision-making, and comprehensive patient education. With the right strategies, remission is now a realistic and achievable goal rather than an exception.

Stay connected and informed—subscribe to RhAPPcast on your favorite podcast platform and visit RhAPP.org for educational resources, faculty insights, and clinical best practices.

The Janus kinase (JAK) family includes four key enzymes: JAK1, JAK2, JAK3, and TYK2. These enzymes play a vital role in transmitting signals within cells, influencing immune response regulation, blood cell production, and cytokine signaling. Each JAK inhibitor has a unique molecular structure and binds to these enzymes with varying degrees of specificity. For example, JAK1 and JAK3 inhibitors regulate cytokines such as IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21, which are essential for immune cell differentiation, function, and survival. JAK2 and TYK2 inhibitors, on the other hand, influence IL-12 and IL-23 signaling, which impact CD4+ T cell differentiation and inflammatory pathways.

Because different JAK inhibitors target distinct JAK proteins, they have varying therapeutic effects and side effect profiles. For instance, inhibiting JAK1 is believed to drive the primary therapeutic benefits of JAK inhibitors in autoimmune diseases. However, inhibiting JAK2 is linked to changes in blood cell production, which may increase the risk of hematologic side effects. Drugs like baricitinib and tofacitinib, which inhibit JAK2 more prominently, are associated with greater changes in blood parameters compared to more JAK1-selective inhibitors like upadacitinib.

While this mechanistic understanding helps guide clinical decision-making, direct head-to-head studies are still needed to fully compare the safety and efficacy of different JAK inhibitors. As the landscape of targeted therapy continues to evolve, clinicians must consider the nuances of JAK inhibition when selecting treatments for autoimmune diseases.

For more insights on JAK inhibitors and their clinical applications, Visit the RhAPP website or explore additional educational content on the RhAPP ACE App.

CD64 upregulation plays a significant role in immune cell activation and inflammation in rheumatic diseases. IL-23 is a key driver of chronic inflammation in the joints, skin, and gut, fueling disease progression in PsA, psoriasis, and IBD. The latest advancements in targeted therapy reveal how IL-23 inhibitors, such as Guselkumab (Tremfya®), utilize CD64 binding to enhance efficacy and improve clinical outcomes.

This discussion explores how CD64 dual binding may refine treatment precision, offering better control of inflammation in PsA, psoriasis, and IBD. Understanding these immunologic pathways is critical for optimizing therapy selection, especially for complex patients requiring tailored treatment approaches.

Stay connected and informed—subscribe to RhAPPcast on your favorite podcast platform and visit RhAPP.org for educational content, expert faculty insights, and practice resources. Visit the RhAPP website or explore additional educational content on the RhAPP ACE App.

Generic drugs are chemically synthesized and identical to their brand-name counterparts in active ingredients, dosage, and administration. They undergo FDA approval based on pharmacokinetic and pharmacodynamic bioequivalence, ensuring the same efficacy and safety profile as the original drug.

Biosimilars, on the other hand, are derived from living cells and are highly similar—but not identical—to biologic reference products. Due to their complex nature, biosimilars require extensive analytical, non-clinical, and clinical studies to confirm structural, functional, and immunogenic similarity. Unlike generics, biosimilars undergo a rigorous FDA approval process that evaluates their efficacy, safety, and therapeutic equivalence through comparative trials rather than simple bioequivalence testing.

With biosimilars becoming increasingly integral to rheumatology and autoimmune disease management, understanding their unique regulatory pathways and clinical implications is essential for informed decision-making.

Want to learn more? Visit the RhAPP website or explore additional educational content on the RhAPP ACE App.

The Oral Surveillance Study was a randomized, open-label, non-inferiority post-authorization safety trial evaluating the safety of JAK inhibitors compared to TNF inhibitors in patients with active rheumatoid arthritis (RA) who were 50 years or older with at least one additional cardiovascular risk factor.

Patients were randomized to receive tofacitinib (5 mg or 10 mg twice daily) or a TNF inhibitor, with the primary endpoints being major adverse cardiovascular events (MACE) and cancers (excluding non-melanoma skin cancer) over a median follow-up of four years.

The study found that patients receiving tofacitinib had a higher incidence of MACE (3.4%) compared to TNF inhibitors (2.5%), with a hazard ratio of 1.33. Similarly, cancer incidence was higher (4.2%) in the tofacitinib group compared to 2.9% in the TNF inhibitor group. These findings did not meet non-inferiority criteria, raising significant safety concerns regarding JAK inhibitors.

As a result, the FDA extended these findings to all JAK inhibitors and restricted their use in RA patients only after failure of a TNF inhibitor. However, some clinicians question the external validity of the study, as it only assessed one JAK inhibitor (tofacitinib). Given differences in JAK receptor selectivity, certain JAK1-selective agents, like upadacitinib, may offer a different safety profile, but further comparative studies are needed.

Until head-to-head studies are conducted, clinicians should follow FDA guidelines, weighing the risks and benefits of JAK inhibitors carefully, particularly in older patients and those with cardiovascular risk factors.

For more expert insights and the latest advancements in rheumatology, download the RhAPP ACE App for valuable resources and clinical updates.

While Ixekizumab is generally well-tolerated, common side effects include injection site reactions, upper respiratory infections, nausea, and fungal infections. More serious risks, such as tuberculosis (TB), bacterial and viral infections, and neutropenia (low neutrophil counts), require careful monitoring. Additionally, some patients may experience worsening of inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, making gastrointestinal evaluation crucial.

To ensure safe and effective treatment, providers should screen for TB before initiating therapy, avoid live vaccines, and monitor blood counts regularly. Caution is advised when combining Ixekizumab with other immunosuppressive agents due to the potential for additive immune suppression.

For more in-depth information on Ixekizumab and its safety in rheumatologic conditions, visit the RhAPP website or explore additional educational content on the RhAPP ACE App.

Patient concerns about medication safety remain a major barrier to initiating biologics and targeted synthetic therapies. This study, published in RMD Open in February 2023, evaluates over 15,000 patient-years of upadacitinib exposure in rheumatoid arthritis, psoriatic arthritis, and atopic dermatitis, providing crucial real-world safety insights.

Findings revealed consistent rates of treatment-emergent adverse events across all disease populations, with slightly higher incidences in rheumatoid and psoriatic arthritis patients. Notably, herpes zoster occurred at a rate of 1.6 to 3.6 per 100 patient-years, reinforcing the importance of vaccination before treatment initiation. Other key safety concerns, including major adverse cardiovascular events (MACE), venous thromboembolism (VTE), and malignancies, were found to be rare and comparable to active comparators such as methotrexate and adalimumab.

The study provides critical data to help clinicians guide informed discussions with patients regarding JAK inhibitor safety. While class-wide black box warnings remain, ongoing research is essential to determine whether risks are drug-specific or apply universally to all JAK inhibitors.

For more expert insights and journal club discussions, visit the RhAPP website, explore the Content Rheum hub, or explore additional educational content on the RhAPP ACE App.

IL-23 is a key cytokine produced by dendritic and macrophage cells, driving TH17 cell differentiation and fueling chronic inflammation. In psoriasis and PsA, dysregulated IL-23 signaling promotes TH17 proliferation, leading to increased IL-17A and IL-17F production—major contributors to inflammation in skin and joints. In IBD, IL-23 plays a similar role, disrupting intestinal barrier integrity and perpetuating chronic inflammation in conditions like Crohn’s disease and ulcerative colitis.

Targeting IL-23 with selective inhibitors has transformed the treatment landscape, offering a precise approach that reduces TH17-driven inflammation while preserving broader immune function. Clinical evidence, including a 2021 Rheumatology Journal publication, underscores IL-23’s pivotal role as the key link between skin, gut, and joint inflammation, making IL-23 inhibition an essential strategy in managing these autoimmune conditions.

IL-23 inhibitors provide effective, targeted therapy, reducing systemic inflammation, improving symptoms, and enhancing long-term patient outcomes across multiple inflammatory diseases.

Want to learn more? Visit the RhAPP website or explore additional educational resources on the RhAPP ACE App.

Kris opens up about his journey with rheumatoid arthritis, from diagnosis to achieving remission with biologic treatment. He discusses his initial concerns about switching to a biosimilar, the misconceptions he encountered, and what the transition was like in the real world. He also highlights the importance of patient-provider communication and how clear guidance from his healthcare team helped make the switch smooth and successful.

Navigating insurance and pharmacy changes can be one of the biggest hurdles in biosimilar adoption. Kris shares his challenges in obtaining approval, adapting to a new injection device, and the crucial role his provider played in easing his transition.

For both patients and providers, this episode underscores the importance of education, trust, and open dialogue when making treatment changes. As biosimilars continue to expand access to life-changing therapies, Kris’s story provides valuable insight into the human side of these transitions.

Visit the RhAPP website or explore additional educational content on the RhAPP ACE App.

Upadacitinib is a selective JAK1 inhibitor used for a range of immune-mediated diseases. In adult patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA), the recommended dose is 15 mg once daily in an extended-release tablet formulation.

For pediatric patients with juvenile idiopathic arthritis (JIA) and PsA, dosing is weight-based using a 1 mg/mL solution:

10-20 kg: 3 mg twice daily

20-30 kg: 4 mg twice daily

≥30 kg: 6 mg twice daily or 15 mg once daily (extended-release tablet)

Higher doses of Upadacitinib are used in gastroenterology and dermatology, particularly for conditions such as Crohn’s disease, ulcerative colitis, and atopic dermatitis, where increased inhibition of inflammatory pathways is required.

Understanding proper dosing is essential for optimizing treatment efficacy while minimizing risks across different patient populations.

For more information on Upadacitinib and its clinical applications, visit the RhAPP website and download the RhAPP ACE App.

The JAK-STAT pathway plays a crucial role in cytokine signaling and immune regulation. Dysregulation of this pathway is a key driver of chronic inflammation in autoimmune diseases, including rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA). Beyond rheumatology, JAK inhibitors are also transforming the treatment landscape in dermatology and gastroenterology, with applications in atopic dermatitis, alopecia areata, lupus, hidradenitis suppurativa, psoriasis, Crohn’s disease, and ulcerative colitis.

STAT proteins, such as STAT1, STAT3, STAT4, and STAT6, contribute to disease pathogenesis by influencing inflammatory processes in the gut, skin, and joints. By selectively inhibiting JAK signaling, JAK inhibitors offer targeted, disease-modifying potential across multiple specialties, providing a new approach to immune modulation.

JAK inhibitors continue to reshape the treatment paradigm in rheumatology, dermatology, and gastroenterology, offering precise immune modulation for chronic inflammatory diseases.

For more in-depth educational content, visit the RhAPP website and explore the RhAPP Content Rheum Hub.

Upadacitinib is a selective JAK1 inhibitor, designed to target cytokine signaling pathways involved in inflammation, immune regulation, and disease progression. By blocking JAK1 signaling, it modulates key immune responses, including cytokine and interferon activity, lipid metabolism, and blood cell development. Compared to broader JAK1/2/3 inhibitors, selective JAK1 inhibition was developed with the goal of reducing risks such as cytopenias and other off-target effects. However, real-world data and clinical outcomes continue to assess whether this theoretical advantage translates into meaningful clinical differences.

JAK inhibitors, including Upadacitinib, remain an essential component of targeted immunomodulation in both pediatric and adult rheumatology, offering treatment options for autoimmune and inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.

Learn more about the latest advancements in JAK inhibitors by visiting the RhAPP website or exploring additional educational content on the RhAPP ACE App.

IL-17A, a pro-inflammatory cytokine produced by TH17 cells, plays a crucial role in driving chronic inflammation in spondyloarthropathies. Elevated IL-17 levels in affected joints and tissues are strongly associated with disease severity in PsA and axial SpA. By promoting neutrophil recruitment and activation, IL-17 contributes to the persistent inflammation, pain, and structural damage characteristic of these conditions.

Unlike broad-spectrum immunosuppressants, IL-17 inhibitors offer a more targeted approach to reducing inflammation. By directly blocking IL-17 signaling, these therapies help to mitigate cytokine overproduction, decrease tissue damage, and improve clinical symptoms. This precision treatment strategy enhances disease control while minimizing the risks associated with broader immunosuppression.

IL-17 inhibition has emerged as a key therapeutic option in PsA, AS, and nr-axSpA, offering improved symptom relief and long-term disease management for patients with these autoimmune-driven conditions.

Stay informed on the latest advances in rheumatology by visiting the RhAPP website or exploring additional educational content on the RhAPP ACE App.

IL-17 is a family of six proteins (IL-17A to IL-17F) that function downstream of IL-23, activating epithelial cells, fibroblasts, and keratinocytes to release inflammatory cytokines and recruit neutrophils. This cascade amplifies immune responses through key signaling pathways, including NF-κB, MAPK, and C/EBP transcription factors. The persistent activation of IL-17-driven inflammation is a hallmark of several rheumatic diseases, making it a significant target for biologic therapies.

For rheumatology APPs, clinicians, and researchers, understanding the IL-17 pathway is essential for optimizing treatment strategies and advancing targeted therapies in autoimmune disease management.

Learn more by visiting RhAPP.org or accessing additional educational content on the RhAPP ACE App.

The JAK-STAT pathway is a key signaling cascade that allows cytokines to regulate immune responses. The process begins when cytokines bind to their respective receptors, triggering the activation of Janus kinases (JAKs). Once activated, JAKs phosphorylate signal transducer and activator of transcription (STAT) proteins, which then translocate to the nucleus to regulate gene expression. Dysregulation of this pathway leads to excessive immune activation, contributing to chronic inflammation and tissue damage in autoimmune conditions.

JAK inhibitors (JAKi) have emerged as a targeted therapeutic approach, blocking key components of the pathway to reduce inflammation and improve disease outcomes. By modulating cytokine signaling, these treatments offer an alternative to traditional biologic therapies in rheumatology and other immune-mediated diseases.

Understanding the JAK-STAT pathway is essential for healthcare providers seeking to optimize treatment strategies for autoimmune diseases.

Learn more by visiting the RhAPP website or exploring additional educational content on the RhAPP ACE App.

Interchangeable biosimilars undergo additional switching studies to confirm that patients can transition seamlessly between the biosimilar and its reference product without concerns about reduced efficacy or increased risks. This designation allows for pharmacy-level substitution in certain states, improving access and affordability for patients managing conditions like rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.

As biosimilars continue to reshape the treatment landscape in rheumatology, understanding interchangeability helps providers and patients make informed decisions.

Learn more about biosimilar approvals, regulatory guidelines, and the broader impact on healthcare sustainability by visiting the RhAPP website or exploring additional educational resources on the RhAPP ACE App.

This discussion highlights a comprehensive integrated analysis of 11 Phase 2 and Phase 3 clinical studies, which pooled over 10,000 patient-years of follow-up data. The results reinforce Guselkumab’s favorable safety profile, demonstrating low rates of severe adverse events, infections, and malignancies, which remained consistent across diverse patient subgroups. Furthermore, adverse event rates during treatment were comparable to those observed during placebo-controlled periods, solidifying Guselkumab as a low-risk, well-tolerated option for long-term management of psoriatic disease.

Visit the RhAPP website or explore additional educational content on the RhAPP ACE App.

Non-responder imputation assumes that participants with missing data are classified as non-responders to treatment. This conservative approach helps maintain trial integrity, prevent bias, and provide a more rigorous evaluation of treatment efficacy. The method is particularly relevant in rheumatology clinical trials, where patient dropout rates can be high.

The FDA often endorses NRI as a gold standard in analyzing trial results, ensuring that reported outcomes are not overly optimistic. However, some argue that NRI can be too conservative, potentially underestimating a treatment’s true effectiveness. This discussion will explore how NRI is applied in rheumatology research, its impact on data interpretation, and its limitations in assessing long-term patient outcomes.

Understanding NRI is essential for clinicians, researchers, and healthcare professionals involved in evaluating new treatments for autoimmune diseases.

Want to learn more? Visit the RhAPP website or access exclusive educational content on the RhAPP ACE App.

As biosimilars gain traction in rheumatology, understanding their role in clinical practice is essential. This discussion breaks down what biosimilars are, how they compare to reference biologics in terms of safety and efficacy, and addresses common misconceptions patients may have when switching to a biosimilar. The conversation also touches on the growing influence of insurance mandates on biosimilar adoption and how APPs can navigate these changes while advocating for patient-centered care.

With insurance providers increasingly driving the shift toward biosimilars, APPs are at the forefront of patient education. This episode equips clinicians with practical strategies, real-world analogies, and evidence-based insights to enhance patient confidence in biosimilar therapy.

Stay connected by subscribing to RhAPPcast on your favorite podcast platform for more in-depth discussions on biosimilars and other critical rheumatology topics.

Want to dive deeper? Explore more on the RhAPP website, the Content Rheum hub, or the RhAPP ACE App.

Ixekizumab is a humanized monoclonal antibody that selectively targets IL-17A, a key pro-inflammatory cytokine involved in the pathogenesis of psoriatic and spondyloarthritic conditions. By inhibiting IL-17A, Ixekizumab helps to reduce inflammation, prevent tissue damage, and alleviate symptoms associated with these chronic conditions. The discussion also covers the role of IL-17A inhibition in both radiographic and non-radiographic axSpA, highlighting its impact on disease progression and patient outcomes.

This session is essential for rheumatology APPs, clinicians, and healthcare providers seeking to stay updated on the latest targeted therapies in autoimmune disease management.

Want to dive deeper? Explore more on the RhAPP website, the Content Rheum hub, or the RhAPP ACE App.

This session provides a comprehensive look at how IL-23 and IL-17 contribute to the pathogenesis of autoimmune conditions, driving chronic inflammation in the skin, joints, and entheses. Understanding the IL-23/IL-17 pathway is key to optimizing targeted therapies for autoimmune disease management.

IL-23 is a pro-inflammatory cytokine produced by dendritic cells and macrophages, stimulating TH17 cell differentiation and leading to IL-17A and IL-17F production. This, in turn, drives neutrophil recruitment and tissue inflammation. Dysregulation of this pathway results in immune activation, leading to the inflammatory plaques seen in psoriasis, joint inflammation in psoriatic arthritis, and enthesitis. Additionally, IL-17 induces the production of other pro-inflammatory mediators such as IL-1β, IL-6, and TNF-α, further amplifying the inflammatory cascade and contributing to disease progression.

This educational session is essential for rheumatology APPs, clinicians, and healthcare professionals seeking to enhance their understanding of targeted immunotherapy.

Want to learn more? Visit the RhAPP website or access exclusive educational content on the RhAPP ACE App.

IL-23 is a key driver of the inflammatory cascade, fueling Th17 cells to produce IL-17A and IL-17F. These cytokines contribute to inflammation in the skin, joints, and gut, making them critical therapeutic targets for autoimmune diseases. With an increasing number of IL-23 and IL-17 inhibitors available, selecting the right therapy for patients involves understanding their unique disease profiles.

The discussion highlights the immunologic link between psoriatic arthritis, psoriasis, and IBD, emphasizing how treatment selection can be tailored to address multiple disease domains. Real-world clinical insights provide a practical perspective on when to prioritize IL-23 inhibitors over TNF blockers and how IL-17A and IL-17F inhibition compares in terms of efficacy and safety. Understanding these mechanisms is essential for healthcare providers managing complex autoimmune conditions, particularly when considering long-term disease control and patient outcomes.

With evolving research and emerging therapies, rheumatology and gastroenterology providers must stay ahead of the latest advances in IL-23 and IL-17 inhibition. For more expert insights, visit RhAPP.org and explore the RhAPP ACE App for the latest in rheumatology education.

Tune in as we explore exciting conference updates, must-attend sessions, cutting-edge research presentations, and unparalleled networking opportunities for advanced practice providers (APPs) in rheumatology. Whether you’re a seasoned rheumatology clinician or new to the field, this CME-accredited event offers a dynamic lineup of educational workshops, expert-led discussions, and hands-on learning experiences to enhance clinical practice and improve patient care.

Visit the RhAPP website or explore additional educational content on the RhAPP ACE App.

In this discussion, Katie explains how IL-23, a heterodimeric cytokine composed of IL-23 p19 and IL-12/23 p40, plays a crucial role in immune system dysregulation. She examines how IL-23 drives inflammation by activating TH17 cells and its connection to key inflammatory mediators, including IL-17, TNF-α, and interferon-gamma. The role of macrophages and dendritic cells in IL-23 secretion across the skin, joints, and gut is also highlighted, emphasizing their impact on disease progression.

By understanding these inflammatory pathways, clinicians can better utilize IL-23 inhibition strategies to manage conditions like psoriasis, psoriatic arthritis, and IBD. This educational session provides valuable insights into the latest advancements in targeted autoimmune therapy.

Want to learn more? Visit the RhAPP website or explore exclusive educational content on the RhAPP ACE App.

In this discussion, Amber explores the differences between Guselkumab and Risankizumab, detailing how their unique mechanisms of action influence therapeutic efficacy. She examines Guselkumab’s CD64 binding compared to Risankizumab’s mutated FC region and highlights how binding affinities may impact drug performance and patient outcomes. Insights from kinetic exclusion assays and flow cytometry provide a deeper understanding of immune cell interactions and the potential for Guselkumab’s CD64 binding to enhance durability and therapeutic response.

For clinicians looking to optimize treatment strategies in psoriatic disease, this comparative analysis provides valuable insights into IL-23 inhibitors and their evolving role in autoimmune therapy.

Stay informed on the latest rheumatology research—visit the RhAPP website or access in-depth educational content on the RhAPP ACE App.

In this video, Danielle explores the role of IL-23 in driving chronic inflammation and autoimmune disease, explaining how TH17 activation contributes to the pathogenesis of psoriasis, psoriatic arthritis, and inflammatory bowel disease. She examines the impact of IL-17A, IL-17F, and IL-22 in skin, joint, and gut inflammation and highlights Guselkumab’s dual-binding mechanism. By targeting both IL-23 and CD64-expressing cells, Guselkumab enhances efficacy while minimizing off-target effects, leading to improved disease outcomes for patients.

For healthcare professionals involved in the management of immune-mediated diseases, understanding IL-23 inhibition is key to optimizing treatment strategies.

Learn more on the RhAPP website or explore exclusive educational content on the RhAPP ACE App.

Humoral immunity, driven by B cells and antibodies, plays a critical role in neutralizing extracellular pathogens, preventing infections, and building long-term immune memory. In contrast, cell-mediated immunity relies on T cells to target intracellular threats, including viruses and cancerous cells. Katie also explores how the IL-23/IL-17 pathway influences immune responses, contributing to autoimmune diseases such as psoriasis and inflammatory arthritis.

This discussion is particularly relevant for APPs and healthcare providers managing autoimmune and infectious diseases. A deeper understanding of these immune pathways enhances clinical decision-making, guiding targeted therapies and vaccine strategies.

For more expert-led content on immunology and autoimmune disease management, visit the RhAPP website or access exclusive resources on the RhAPP ACE App.

Lindsay Tom shares insights from her compelling piece, "From Joints to Bones: The Crucial Role of Rheumatology Providers in Osteoporosis Care." Osteoporosis, a chronic and progressive bone disease that leads to fragility fractures, is a major public health concern affecting millions of Americans, particularly postmenopausal women and individuals on long-term glucocorticoid therapy. Despite its prevalence and severe consequences, osteoporosis remains underdiagnosed and undertreated, making rheumatology providers essential in bridging the care gap.

This episode explores the latest advancements in osteoporosis management, including the importance of dual-energy X-ray absorptiometry (DXA) scanning for early detection, the use of FRAX (Fracture Risk Assessment Tool) in guiding treatment decisions, and the evolving landscape of pharmacologic therapies, such as bisphosphonates, anabolic agents like teriparatide and romosozumab, and RANK ligand inhibitors like denosumab.

Listeners will gain valuable insights into patient-centered care approaches, including fall prevention strategies, nutritional optimization with calcium and vitamin D, the role of weight-bearing exercises, and the impact of lifestyle modifications on bone health. This discussion will also highlight how advanced practice providers (APPs) can play a pivotal role in multidisciplinary care, working alongside endocrinologists, primary care physicians, orthopedic specialists, and physical therapists to improve patient outcomes.

Whether you are an NP, PA, or physician specializing in rheumatology, endocrinology, or musculoskeletal medicine, this episode provides actionable knowledge for early intervention, comprehensive patient education, and optimizing osteoporosis treatment in both outpatient and inpatient settings.

Visit the RhAPP website or explore additional educational content on the RhAPP ACE App.

Dr. Cayla Alexander shares her unique perspective in her thought-provoking piece, "Axial Spondyloarthritis: At the Intersection of Clinician and Patient," examining the challenges of early diagnosis, treatment barriers, and the evolving role of advanced practice providers (APPs) in managing this complex disease. Axial spondyloarthritis, which includes ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA), is often misdiagnosed or delayed due to its overlap with mechanical back pain and a lack of awareness among primary care providers (PCPs) and orthopedic specialists.

This episode delves into the latest advancements in axSpA management, including the role of biologic therapies such as TNF inhibitors and IL-17 inhibitors, the importance of MRI in early detection, and how APPs can play a pivotal role in multidisciplinary care alongside rheumatologists, physical therapists, and pain specialists.

Listeners will gain valuable insights into patient-centered care strategies, including shared decision-making, lifestyle interventions, and the importance of mental health support for those living with chronic inflammatory arthritis. Whether you’re an NP, PA, or physician specializing in rheumatology, pain management, or musculoskeletal medicine, this episode provides actionable knowledge for optimizing axial spondyloarthritis diagnosis and treatment.

Visit the RhAPP website or explore additional educational content on the RhAPP ACE App.

Interstitial lung disease (ILD) is a growing concern in rheumatology and pulmonary medicine, with early detection being critical for improving patient outcomes and slowing disease progression. In this episode, we discuss best practices for ILD screening and management, the evolving role of advanced practice providers (APPs) in multidisciplinary care, and how innovative diagnostic tools such as HRCT scans and PFTs are transforming the way we detect and treat autoimmune-related lung diseases.

Listeners will gain valuable insights from Corinne Young, a nationally recognized pulmonary care expert who shares her clinical expertise and strategies for optimizing ILD management in both hospital-based and private practice settings across the United States. With a strong focus on APP-led care teams, collaborative treatment models, and emerging research in pulmonology and rheumatology, this discussion is ideal for nurse practitioners (NPs), physician assistants (PAs), and other healthcare professionals specializing in rheumatologic and respiratory diseases.

Stay ahead in advanced practice provider education and collaborative care models by tuning into RhAPPcast, your go-to podcast for the latest developments in rheumatology, pulmonology, and multidisciplinary patient management.

Visit the RhAPP website or explore additional educational content on the RhAPP ACE App.

Know an APP in pulmonology or interested in pulmonology? Registration for the inaugural APAPP National Conference, happening 6/20-6/22/24 in Las Vegas, NV is now open and available here!

Learn about the key challenges, learning curves, and best practices in adopting a rheumatology-focused approach to patient care. Whether you're an APP, rheumatology professional, or medical student, this episode provides essential knowledge on career growth, patient management, and clinical expertise in rheumatology.

Tune in to RhAPPcast, the leading podcast for advanced practice providers in rheumatology, and stay at the forefront of specialty care and professional development.

Visit the RhAPP website or explore additional educational content on the RhAPP ACE App.

With decades of experience in rheumatology, Dr. Cush shares his perspective on leadership in this rapidly evolving specialty. Together, they explore what it takes to guide and inspire the next generation of rheumatology providers, the importance of staying ahead in an ever-changing medical landscape, and the role of education and advocacy in shaping the future of the field. Whether you're an experienced clinician or an early-career APP, this conversation offers valuable insights into the skills and mindset needed to lead in rheumatology today.

Visit the RhAPP website or explore additional educational content on the RhAPP ACE App.

Rheum Now Live is happening 1/27-1/28/24, registration and details available here: https://rheumnow.live/

Throughout the conversation, Gabriella and Jamie explore the challenges of discussing biosimilars with patients and the best methods to explain their role in treatment. They dive into common misconceptions, including patient hesitancy about switching from reference biologics, and examine how to navigate these conversations with clarity and empathy. A key focus of the discussion is the nocebo effect—how negative patient expectations can influence treatment outcomes—and they share strategies to counteract these concerns through effective counseling and reassurance.

Beyond addressing patient apprehensions, the episode highlights the many benefits of biosimilars, including improved accessibility, affordability, and the potential for broader treatment options. By fostering open and informed conversations, APPs can ensure that patients feel confident in their treatment decisions and embrace biosimilars as a viable and effective option.

This final episode is a must-listen for healthcare providers looking to strengthen their approach to biosimilar discussions and enhance patient trust in these evolving therapies.

Visit the RhAPP website or explore additional educational content on the RhAPP ACE App.

Please take our evaluation regarding this podcast here:   https://www.rhapp.org/bio-podcast-eval

As biosimilars continue to reshape treatment options in gastroenterology and rheumatology, understanding the nocebo effect—where negative patient expectations contribute to perceived or real adverse effects—becomes essential for advanced practice providers (APPs).

Throughout this episode, Amanda and Naomi explore, the science behind the nocebo effect and how it differs from the placebo effect. Key research findings on the impact of the nocebo effect in biosimilar use. Real-world clinical implications of negative patient perceptions and how they can affect treatment adherence. Practical strategies to counteract the nocebo effect, including effective patient counseling, education, and communication techniques.

This episode is packed with valuable insights for APPs navigating biosimilar adoption and looking to build patient trust and confidence in these treatments.

Tune in to gain a deeper understanding of patient psychology and learn how proactive communication can enhance patient outcomes in biosimilar therapy!

Please take our evaluation regarding this podcast here: https://www.rhapp.org/bio-podcast-eval

Dr. Feldman introduces the Coalition of State Rheumatology Organizations (CSRO), a powerful group dedicated to advancing policies that improve rheumatology care. She shares how RhAPP members can get involved, make an impact, and advocate for better patient outcomes and healthcare policies.

Whether you're an APP, physician, or healthcare professional, this episode offers valuable insights into how advocacy shapes rheumatology practice and improves patient care.

Visit the RhAPP website or explore additional educational content on the RhAPP ACE App.

They begin by reviewing key takeaways from the AGA Biosimilars Roundtable Meeting Report and the Crohn’s & Colitis Foundation Biosimilar Position Statement, which provide guidance on biosimilar safety, efficacy, and implementation in IBD treatment.

Sharon shares insights on biosimilars in Crohn’s disease and ulcerative colitis, discussing their effectiveness, safety, and patient outcomes. They examine how APPs can lead patient education, navigate insurance-mandated transitions, and optimize prior authorization processes to ensure seamless integration of biosimilars into practice.

Addressing common hesitations, they highlight the rigorous FDA approval process, real-world evidence, and provider confidence-building strategies. With practical tips for overcoming barriers, this episode serves as a concise guide for GI APPs adopting biosimilars in clinical care.

Tune in to gain actionable strategies for implementing biosimilars in gastroenterology and stay connected for the next episode in the GHAPP & RhAPP Biosimilar Podcast Series.

Visit the RhAPP website or explore additional educational content on the RhAPP ACE App.

Please take our evaluation regarding this podcast here:  https://www.rhapp.org/bio-podcast-eval

The conversation kicks off with an exploration of the American College of Rheumatology (ACR) White Paper on Biosimilars, which serves as a guiding document for rheumatology providers navigating the evolving landscape of biologic therapy. Amanda and Daric break down key takeaways from the white paper, including the rigorous standards biosimilars must meet to gain FDA approval, their comparable efficacy and safety profiles to reference biologics, and the regulatory distinctions between biosimilars and interchangeable biosimilars.

A major focus of the discussion revolves around the clinical use of biosimilars in rheumatic diseases. With biosimilars now available for conditions like rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, APPs must stay informed on their role in treatment algorithms. Daric shares insights on selecting the right biosimilar for individual patients, the impact of payer-driven formularies, and considerations for switching stable patients from a reference biologic to a biosimilar.

One of the most critical aspects of biosimilar adoption is implementation in rheumatology practice. Amanda and Daric outline strategies for integrating biosimilars into treatment plans, addressing common concerns from patients and providers. They emphasize the importance of patient education, transparency in communication about biosimilar safety and efficacy, and the need for ongoing provider engagement with payers to ensure seamless access. They also discuss practical steps for navigating insurance-mandated biosimilar substitutions, prior authorization processes, and formulary restrictions.

Throughout the episode, Daric highlights real-world experiences with biosimilars in clinical practice, detailing how increased affordability and access have positively impacted patient outcomes. He also discusses challenges, such as overcoming patient hesitancy and provider resistance to change, and offers solutions to streamline the transition process.

This episode provides a comprehensive guide for rheumatology APPs looking to integrate biosimilars effectively into their practice. Whether you’re considering biosimilars for new patients or transitioning existing patients, Amanda and Daric’s insights will help you feel confident in navigating the biosimilar landscape.

Visit the RhAPP website or explore additional educational content on the RhAPP ACE App.

Please take our evaluation regarding this podcast here:  https://www.rhapp.org/bio-podcast-eval

The conversation opens with a critical discussion on affordability. Biosimilars offer significant cost reductions compared to their reference biologics, making life-changing treatments more accessible to patients. A 2022 report from the Association for Accessible Medicines highlighted that the average sale price of biosimilars is 50% lower than their reference biologic, with competition driving down the price of brand-name biologics by an average of 25%. This translates into substantial cost savings for patients, insurers, and the healthcare system, with some studies showing that patients switching to biosimilars can save as much as $6,000 annually.

Beyond affordability, biosimilars increase access to biologic therapies, ensuring that more patients receive the treatment they need without financial barriers. Gwen shares real-world examples of patients struggling with medication affordability and how biosimilars have improved adherence by reducing out-of-pocket costs. With increased medication adherence, patients experience better disease control, reducing the risk of severe flare-ups, hospitalizations, and costly interventions.

From a broader healthcare perspective, biosimilars drive cost-effectiveness by fostering healthy market competition. Their introduction forces biologic manufacturers to reconsider pricing strategies, ultimately leading to lower costs for all stakeholders. This also strengthens the negotiating power of insurers and healthcare providers, enabling them to secure better reimbursement rates and treatment coverage for patients.

An often-overlooked aspect of biosimilars is their role in fostering medical innovation. Because biosimilars require manufacturers to develop novel yet comparable production processes, they encourage advancements in bioprocessing, quality control, and drug manufacturing. Additionally, increased competition from biosimilars incentivizes pharmaceutical companies to invest in research and development, leading to new and improved therapies, novel drug delivery systems, and better treatment options for patients.

The discussion also explores how biosimilars contribute to the transition from volume-based to value-based care. Unlike volume-based models, which prioritize the quantity of services delivered, value-based care focuses on quality outcomes, patient health, and cost savings. Biosimilars align with this approach by offering high-quality treatment at a reduced cost, allowing healthcare systems to allocate resources more efficiently and improve overall patient care.

Gwen shares a personal story about her family’s experience with biosimilars, underscoring the real-world impact these medications can have on patients facing financial and insurance barriers. Her insights highlight the importance of patient education and transparent communication when discussing biosimilar transitions. While some patients may initially express concerns about switching from a reference biologic, clear discussions about biosimilar safety, efficacy, and cost benefits can ease their worries and encourage adherence.

As the biosimilar landscape continues to evolve, healthcare providers play a crucial role in ensuring a smooth transition for patients. By fostering confidence in biosimilars and reinforcing their proven efficacy, providers can help patients make informed decisions about their treatment options.

Don’t miss this insightful discussion on the benefits of biosimilars in GI and rheumatology. Tune in to this episode of the GHAPP & RhAPP Biosimilar Podcast Series to learn how biosimilars are transforming patient care, lowering costs, and advancing the future of medicine

Visit the RhAPP website or explore additional educational content on the RhAPP ACE App.

Please take our evaluation regarding this podcast here:  https://www.rhapp.org/bio-podcast-eval

Managed care plays a pivotal role in the healthcare ecosystem, aiming to improve quality while controlling costs. As biosimilars continue to gain traction, their inclusion in formularies, utilization management strategies, and patient education initiatives become essential components of managed care frameworks. Audrey explains that the introduction of biosimilars brings substantial cost savings by fostering price competition and broadening patient access to biologic therapies. By negotiating contracts with biosimilar manufacturers, payers can help reduce the financial burden on both patients and the healthcare system.

One of the key challenges in biosimilar adoption is provider and patient familiarity with these therapies. While providers may hesitate to transition patients from a reference biologic, understanding the extensive FDA approval process and clinical trials supporting biosimilar safety and efficacy helps build confidence. Studies such as NOR-SWITCH and VOLTAIRE have demonstrated that biosimilars maintain the same therapeutic effect as reference biologics, reinforcing their reliability.

Audrey also highlights the importance of formulary management, utilization strategies such as step therapy and prior authorization, and patient education as critical factors in managed care adoption of biosimilars. Effective communication about biosimilar benefits can ease concerns and improve adherence, ensuring patients receive timely and effective treatment.

The discussion underscores that while managed care organizations play a vital role in biosimilar uptake, providers must also engage in transparent conversations with patients. Addressing concerns about switching therapies and educating patients on cost savings and comparable efficacy is key to a smooth transition.

With biosimilars becoming an increasingly essential part of treatment landscapes in gastroenterology and rheumatology, understanding their role within managed care is critical. Tune in to this episode of the GHAPP & RhAPP Biosimilar Podcast Series to gain deeper insights into how managed care is shaping the future of biosimilar adoption and patient access.

Subscribe to RhAPPcast and follow RhAPP on social media for updates, and explore the RhAPP ACE App for educational resources designed for rheumatology APPs.

Please take our evaluation regarding this podcast here:  https://www.rhapp.org/bio-podcast-eval

Janette breaks down the rigorous FDA approval process required for a biosimilar to be designated as interchangeable. Unlike generics, biosimilars are highly complex medications derived from living cells, making them similar—but not identical—to their reference products. Interchangeable biosimilars must undergo additional switch studies to confirm that patients can transition between the reference product and the biosimilar without compromising safety, efficacy, or immunogenicity. While all biosimilars must demonstrate equivalency, only a select few receive official interchangeability status, allowing for pharmacy-level substitution without provider intervention.

The discussion highlights key clinical trials that have shaped biosimilar adoption. The NOR-SWITCH trial played a pivotal role in confirming that patients across multiple disease states, including Crohn’s disease, ulcerative colitis, and rheumatoid arthritis, maintained stable outcomes when switched from the reference biologic to a biosimilar. The VOLTAIRE studies provided further evidence supporting the safety and efficacy of biosimilar switching, particularly with adalimumab.

As biosimilars become increasingly integrated into clinical practice, providers must navigate insurance-driven formulary changes and patient concerns about transitioning from brand-name biologics. While data supports the safety and effectiveness of biosimilar switching, patient education remains key. The conversation emphasizes the importance of transparency, addressing the nocebo effect, and advocating for patients when necessary.

This episode underscores the need for APPs to stay informed about biosimilars, regulatory processes, and the evolving landscape of biologic treatments in gastroenterology and rheumatology. As the market grows, so does the opportunity to expand access to effective, lower-cost therapies for patients

Subscribe to RhAPPcast and follow RhAPP on social media for updates, and explore the RhAPP ACE App for educational resources designed for rheumatology APPs.

Please take our evaluation regarding this podcast here: https://www.rhapp.org/bio-podcast-eval

Daric shares his journey into rheumatology, from an early interest in healthcare to a career shaped by a formative rotation that sparked his passion for the specialty. He discusses the intellectual challenges and rewards of working in rheumatology, emphasizing the puzzle-solving nature of diagnosing and managing complex autoimmune conditions. With experience in a private practice setting, Daric details how his day-to-day role integrates continuity of care, patient relationships, and evolving treatments.

A major focus of this episode is multidisciplinary care, particularly bridging communication gaps between rheumatology and ophthalmology. Daric shares key strategies for enhancing collaboration, including open dialogue, shared clinical goals, and mutual education between specialties. He highlights how ophthalmologists often rely on rheumatologists' expertise when it comes to advanced biologic therapies, and how strengthening these professional relationships can lead to better patient care.

For new APPs, Daric provides valuable advice on integrating into rheumatology, from finding the right mentor and leveraging educational resources to actively engaging in professional networks like RhAPP. His passion for advancing APP education and multidisciplinary collaboration makes this episode a must-listen for anyone in rheumatology, ophthalmology, or beyond.

Follow RhAPPcast and RhAPP on social media for updates, and explore the RhAPP ACE App for educational resources designed for rheumatology APPs.

Biosimilar extrapolation allows regulatory bodies like the FDA to approve biosimilars for multiple indications without requiring separate clinical trials for each condition. Instead, this approval is based on scientific justification, drawing from data on mechanism of action (MOA), pharmacokinetics (PK), immunogenicity, and overall biosimilarity to the reference product. By streamlining the approval process, extrapolation helps expand access to these treatments, making biologic therapies more affordable and widely available for patients in gastroenterology and rheumatology.

During the discussion, Amanda and Betsy break down key aspects that support scientific justification for extrapolation, including how MOA remains consistent across different disease states, how PK and biodistribution studies confirm that the biosimilar behaves like its reference product, and how expected toxicities remain in line with the reference biologic. They also touch on real-world implications, such as insurance-driven biosimilar switches and how APPs can educate and reassure patients about biosimilar safety and efficacy.

The conversation underscores the rigorous data-driven approach behind biosimilar extrapolation, reassuring clinicians and patients alike that these therapies undergo comprehensive analytical and clinical evaluations before approval. As biosimilars become a mainstay in the treatment of IBD, rheumatoid arthritis, and other chronic inflammatory diseases, understanding extrapolation is key for APPs, pharmacists, and physicians navigating biosimilar adoption in practice.

Stay informed on the latest developments in biosimilars and rheumatology & GI care by subscribing to the GHAPP & RhAPPcast podcast series and accessing expert-driven resources on the RhAPP ACE App.

Please take our evaluation regarding this podcast here: https://www.rhapp.org/bio-podcast-evall

This episode unpacks the fundamental distinctions between biosimilars and generics, including molecular size and structure, complexity of development, and cost of production. While generics are identical copies of small-molecule drugs, biosimilars are highly similar but not identical to biologic medications, requiring an extensive approval process to confirm safety, efficacy, and immunogenicity. With biologic treatments playing a critical role in managing IBD, rheumatoid arthritis, and other chronic inflammatory diseases, understanding these differences is crucial for advanced practice providers (APPs) navigating biosimilar adoption in clinical settings.

Throughout the conversation, Gabriella and Tedra discuss key regulatory and clinical aspects of biosimilars, emphasizing how the FDA’s totality of evidence approach ensures their safety and effectiveness. They also address the real-world impact of biosimilars, particularly as insurance-driven transitions become more common. The episode highlights strategies for educating patients, overcoming treatment hesitancy, and advocating for cost-effective, high-quality care while maintaining disease control and remission.

With biosimilar adoption expanding, APPs play a vital role in guiding patients through treatment transitions, ensuring they receive the same level of efficacy and safety as with reference biologics. Whether you're an APP, pharmacist, physician, or healthcare professional, this episode provides the knowledge and confidence needed to navigate biosimilar implementation in gastroenterology and rheumatology practice.

Stay ahead of the curve—subscribe to GHAPP & RhAPPcast on your favorite podcast platform and download the RhAPP ACE App for expert-driven resources, clinical updates, and continuing education on biosimilars and advanced rheumatology practice

Please take our evaluation regarding this podcast here: https://www.rhapp.org/bio-podcast-eval

In this episode, we explore the totality of evidence approach, a rigorous evaluation process used by the FDA to determine biosimilarity. The discussion breaks down analytical testing for structural and functional characterization, nonclinical safety assessments, and comparative human pharmacokinetic (PK) and pharmacodynamic (PD) studies—all key components that ensure biosimilars match the safety and efficacy of their reference biologics. Additionally, immunogenicity assessments and comparative clinical studies are examined, offering valuable insight into how biosimilars gain regulatory approval.

Biosimilars provide an opportunity to expand patient access to biologic therapies while addressing cost concerns in the healthcare system. However, insurance-driven switches and provider hesitancy require APPs to be well-versed in the regulatory pathway and confident in their ability to educate patients. This conversation highlights how biosimilars are evaluated at every stage—from structural integrity to real-world efficacy—ensuring no clinically meaningful differences exist compared to reference products.

With biosimilars becoming more common, particularly in subcutaneous therapies, understanding their approval process is more important than ever. Whether you’re a rheumatology or gastroenterology provider, a clinical pharmacist, or a healthcare professional seeking clarity on biosimilars, this episode offers the expertise needed to navigate the future of biologic treatment options.

Stay informed and enhance your clinical knowledge—subscribe to RhAPPcast on your favorite podcast platform and download the RhAPP ACE App for access to expert-driven resources, clinical updates, and continuing education in biosimilars and advanced rheumatology practice.

Please take our evaluation regarding this podcast here: https://www.rhapp.org/bio-podcast-eval

This episode takes a deep dive into the scientific and regulatory journey behind biosimilars, breaking down the extensive research, rigorous clinical testing, and advanced manufacturing techniques that ensure these therapies match the safety and efficacy of their reference biologics. The discussion sheds light on the analytical testing required to establish biosimilarity, the importance of immunogenicity assessments, and the real-world implications of biosimilars in clinical practice. With rheumatology and gastroenterology providers at the forefront of patient education, the conversation also highlights the importance of understanding biosimilar naming conventions, explaining the rationale behind the structured FDA suffix system and how it impacts prescribing.

Biosimilars offer a promising avenue for increasing patient access to biologic therapies while reducing healthcare costs. However, ensuring a smooth transition for patients requires APPs to stay informed and confident in explaining the role of biosimilars in treatment plans. As insurance mandates shift prescribing patterns, the need for clarity around biosimilars has never been more critical. Tanya Golovanoff’s expertise provides a clear and compelling perspective on how biosimilars are developed, manufactured, and named, offering valuable insights for healthcare providers managing treatment decisions in gastroenterology, rheumatology, and immunology.

Tune in to this engaging discussion and stay ahead of the latest advancements in biosimilars. Subscribe to GHAPP & RhAPPcast on your favorite podcast platform and explore expert-driven resources on the RhAPP ACE App to enhance your clinical knowledge and support optimal patient care.

Please take our evaluation regarding this podcast here: https://www.rhapp.org/bio-podcast-eval

Explore the challenges, milestones, and driving passion that led to RhAPP’s success, as Amanda and Betsy reflect on their vision to create a thriving community of APPs specializing in rheumatology. Learn how RhAPP’s educational initiatives, mentorship programs, and advocacy efforts continue to empower nurse practitioners (NPs), physician assistants (PAs), and other APPs, ensuring they have the resources and support needed to provide exceptional patient care.

Whether you’re a seasoned rheumatology APP or just beginning your journey, this episode offers valuable insights into the impact of RhAPP and how its mission continues to transform the landscape of rheumatology practice.

Stay connected with the latest in rheumatology education, clinical updates, and professional development—subscribe to RhAPPcast on your favorite podcast platform and download the RhAPP ACE App for expert insights and resources tailored for APPs in rheumatology.

This discussion begins by defining biologic therapy and how these complex treatments, derived from living organisms, are designed to modulate the immune system in conditions like inflammatory bowel disease (IBD), rheumatoid arthritis (RA), and psoriatic arthritis (PsA). Jennifer explains the key differences between biologics and biosimilars, including why biosimilars are not identical to generics and how they maintain comparable safety, efficacy, and immunogenicity to their reference biologics.

A major focus of this episode is the regulatory approval process, including how the Biologics Price Competition and Innovation Act (BPCIA) streamlined biosimilar development to enhance patient access and affordability. The conversation also explores the role of the FDA in biosimilar approval, the importance of real-world switch data, and how state laws and insurance policies influence biosimilar prescribing.

One of the biggest patient concerns with biosimilars is the fear of disease flare-ups or new side effects when transitioning from a reference biologic. Jennifer shares practical communication strategies to reassure patients, address common misconceptions, and navigate payer-mandated switches. The discussion also highlights the economic benefits of biosimilars, emphasizing how they help reduce costs for both healthcare systems and patients while maintaining high treatment standards.

Visit the RhAPP website or explore additional educational content on the RhAPP ACE App.

Please take our evaluation regarding this podcast here: https://www.rhapp.org/bio-podcast-eval